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ABSTRACT
THE QUANTITATIVE ASSESSMENT OF OSTEOINDUCTIVITY OF
HUMAN DEMINERALIZED BONE MATRIX AND cDNA ARRAY ANALYSIS OF
OSTEOGENIC DIFFERENTIATION IN HUMAN PERIOSTEAL CELLS
Sittisak Honsawek
Old Dominion University and Eastern Virginia Medical School, 2003
Director: Dr. Lloyd Wolfinbarger, Jr.

Demineralized bone matrix (DBM) has been extensively utilized in orthopeadic,
periodontal, and maxillofacial applications. DBM comprises bone morphogenetic
proteins (BMPs) that are essential regulators for endochondral bone formation. The
current study was undertaken to establish the quantitative in vitro assays for determining
the osteoinductive potential of human DBM and the use of cDNA gene expression array
technology for examining gene expression profiles during osteoblast differentiation in
human periosteal cells.
BMP-4 is one of the most osteoinductive factors and has been investigated for
clinical applications. For this reason, BMP-4 was designated as the osteoinductive
protein for use in the quantitative in vitro assay. At the same time, the osteoinductivity of
DBM was measured by histomorphometric analysis of new bone formation in an in vivo
athymic mouse bioassay. DBM exhibiting high osteoinductivity in the nude mouse
bioassay contained higher amounts of extractable BMP-4 than did DBM samples
possessing low osteoinductivity.
In the study of the effect of residual calcium on extractability of BMP-4, the
extractable BMP-4 content was undetectable in nondemineralized bone matrix. As the
residual calcium level decreased, the extractability ofBMP-4 in DBM increased. DBM
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particles less than 250 microns yielded the lowest amounts of extractable BMP-4 among
all size groups tested. Bone particles in the 500-710 micron size range provided for
DBM with the highest extractability of BMP-4. In the donor age study, the BMP-4
content in the protein extracts of DBM appears to be age-dependent, with DBM from
younger donors being most likely to have greater BMP-4 quantity.
In the in vitro dose-response studies, DBM-conditioned media (DBM-CM)
enhanced alkaline phosphatase activities of human periosteal cells in a dose-dependent
fashion. Alkaline phosphatase activities in both biochemical and histochemical analysis
increased in the DBM-CM treated flasks compared to non-treated flasks after five days of
incubation. In gene expression analysis of osteogenic differentiation using cDNA array
analysis, a few differentially expressed genes, including biglycan, TGF-pi, and TGF-|3R1
were up-regulated, whereas collagenl4Al was down-regulated in response to DBM-CM
treatment. In the present study, gene expression array technology provides insight to the
biological process of osteogenic differentiation.
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1
INTRODUCTION

1. BONE
Bone consists of cells and extracellular matrix. The extracellular bone matrix is
comprised of 35% organic and 65% inorganic components. The inorganic components
are mainly calcium and phosphate as hydroxyapatite. The organic components of bone
matrix are divided into collagen and noncollagenous proteins. Type I collagen
constitutes more than 90% of the organic material in bone matrix and is the major
structural protein of bone. The remaining 10%, the non-collagenous proteins, have
different regulatory functions for mineralization, mediation of cell-to-matrix binding, and
various interactions with structural proteins, such as collagen. Cells responsible for the
production of the bone matrix constituents collagen and ground substance are boneforming cells or osteoblasts. The mature osteoblasts are post-proliferative, cuboidal,
strongly alkaline phosphatase positive cells lining bone matrix at sites of active matrix
production. The mature osteoblast phenotype is characterized by the ability of the cells
to synthesize membrane-associated alkaline phosphatase, bone matrix molecules
including type I collagen, and a variety of non-collagenous proteins, such as osteocalcin,
and bone sialoprotein.
1.1 Bone cells
Four primary cell types are responsible for the formation and resorption of mature
bone: (1) osteoblasts, (2) osteocytes, (3) lining cells, and (4) osteoclasts.

The journal model is Journal o f Dental Research.
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1.1.1 Osteoblasts
The fully differentiated osteoblasts produce and secrete proteins that constitute the
bone matrix (Robey et a l, 1995). The matrix is subsequently mineralized under the
control of the same cells. A major product of the bone-forming osteoblast is type I
collagen. This polymeric protein is initially secreted in the form of a precursor, which
contains peptide extensions at both the amino-terminal and carboxyl ends of the
molecule. The propeptides are proteolytically cleaved. Further extracellular processing
results in mature three-chained type I collagen molecules, which then assemble
themselves into a collagen fibril. Individual collagen molecules become interconnected
by the formation of pyridinoline cross-links, which are unique to bone. Bone-forming
osteoblasts synthesize a number of other proteins that are incorporated into the bone
matrix, including osteocalcin and osteonectin, which constitute 40% to 50% of the
noncollagenous proteins of bone. Mice deficient in osteocalcin develop a phenotype
marked by higher bone mass and improved bone quality suggesting that osteocalcin
functions normally to limit bone formation without compromising mineralization (Ducy
et al, 1996). Conversely, mice deficient in osteonectin exhibit decreased osteoclast and
osteoblast numbers and bone remodeling and profound osteopenia suggesting that under
normal conditions, this protein may play a role in the birth or survival of these cells
(Delany et a l, 1998). Other osteoblast-derived proteins include glycosaminoglycans,
which are attached to one of two small core proteins: biglycan and decorin. The latter
protein has been implicated in the regulation of collagen fibrillogenesis. A number of
other minor proteins such as osteopontin, bone sialoprotein, fibronectin, vitronectin, and
thrombospondin serve as attachment factors that interact with integrins.
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In addition to being the cells that produce the osteoid matrix, mature osteoblasts
are essential for its mineralization, the process of deposition of hydroxyapatite (Boskey,
1998; 1996). Osteoblasts are thought to regulate the local concentrations of calcium and
phosphate in such a way as to promote the formation of hydroxyapatite. Osteoblasts
express relatively high amounts of alkaline phosphatase, which is anchored to the
external surface of the plasma membrane. Alkaline phosphatase has been thought to play
a role in bone mineralization. Consistent with this, deficiency of alkaline phosphatase
due to genetic defects leads to hypophosphatasia, a condition characterized by defective
bone mineralization (Whyte, 1994). However, the precise mechanism of mineralization
and the exact role of alkaline phosphatase in this process remain unclear. Matrix
synthesis determines the volume of bone but not its density. Mineralization of the matrix
increases the density of bone by displacing water, but does not alter its volume.
1.1.2 Osteocytes
Some osteoblasts are eventually buried within lacunae of mineralized matrix.
These cells are termed osteocytes and are characterized by a striking stellate morphology,
reminiscent of the dendritic network of the nervous system (Marotti et a l, 1990;
Nijweide et al., 1996). Osteocytes are the most abundant cell type in bone. Osteocytes
are 10 times more than osteoblasts. Osteocytes are regularly spaced throughout the
mineralized matrix and communicate with each other and with cells on the bone surface
via multiple extensions of their plasma membrane that run along the canaliculi.
Osteoblasts, in turn, communicate with cells of the bone marrow stroma which extend
cellular projections onto endothelial cells inside the sinusoids. Thus, a syncytium extends
from the embedded osteocytes all the way to the vessel wall (Marotti, 1996). Osteocytes
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sense changes in interstitial fluid flow through canaliculi and detect changes in the levels
of hormones, such as estrogen and glucocorticoids, that influence their survival and that
circulate in the same fluid (Weinstein et al., 1998; Tomkinson et al.^ 1998; 1997).
Therefore, disruption of the osteocyte network is likely to increase bone fragility.
1.1.3 Lining cells
The surface of normal quiescent bone is covered by a 1-2 pm thick layer of
unmineralized collagen matrix on top of which there is a layer of flat and elongated cells.
These cells are called lining cells and are descendents of osteoblasts (Parfitt, 1994).
Conversion of osteoblasts to lining cells represents one of the fates of osteoblasts that
have completed their bone forming function. Osteoclasts cannot attach to the
unmineralized collagenous layer that covers the surface of normal bone. Therefore, the
lining cells secrete collagenase, which removes this matrix before osteoclasts can attach
to bone. Targeting of osteoclast precursors to a specific location on bone depends on a
homing signal given by lining cells. The lining cells are signaled by osteocytes.
Osteocytes are the only bone cells that can sense the need for remodeling at a specific
time and place (Parfitt etal., 1996).
1.1.4 Osteoclasts
Mature osteoclasts are usually large multinucleated cells with abundant
mitochondria, numerous lysosomes, and free ribosomes. Their most remarkable
morphological feature is the ruffled border, a complex system of finger-shaped
projections of the membrane. Its function is to mediate the resorption of the calcified
bone matrix (Roodman, 1996; Boskey, 1998). This structure is completely surrounded
by another specialized area, called the clear zone. The cytoplasm in the clear zone area
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has a uniform appearance and contains bundles of actin-like filaments. The clear zone
delineates the area of attachment of the osteoclast to the bone surface and seals off a
distinct area of the bone surface that lies immediately underneath the osteoclast and
which eventually will be excavated. The ability of the clear zone to seal off this area of
bone surface allows the formation of a microenvironment suitable for the operation of the
resorptive apparatus.
The mineral component of the matrix is dissolved in the acidic environment of the
resorption site, which is created by the action of an ATP-driven proton pump located in
the ruffled border membrane. The protein components of the matrix, mainly collagen,
are degraded by matrix metalloproteinases, and cathepsins K, B, and L are secreted by
the osteoclast into the area of bone resorption (Bossard et al., 1996). The degraded bone
matrix components are endocytosed along the ruffled border within the resorption
lacunae and then transcytosed to the membrane area opposite the bone, where they are
released (Nesbitt etal., 1997; Salo et al., 1997). Another feature of osteoclasts is the
presence of high amounts of the phosphohydrolase enzyme, tartrate-resistant acid
phosphatase (TRAPase). This feature is commonly used for the detection of osteoclasts
in bone specimens (Udagawa et al, 1990). Mice deficient in TRAPase exhibit a mild
osteopetrotic phenotype due to an intrinsic defect of osteoclastic resorptive activity and
defective mineralization of the cartilage in developing bones (Hayman et al., 1996).
1.2 Bone matrix
The mineral phase of bone is nucleated, propagated, and remodeled within the
scaffolding provided by the extracellular matrix. This organic scaffolding consists
primarily of large protein components that have the capacity to form macromolecular
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aggregates, the organization of which establishes the bone superstructure. Also
incorporated into the scaffolding superstructure are relatively small proteins that appear
to act in the communication between the matrix and the cells in bone (Gehron et al.,
1996). The matrix components of bone consist of three classes of macromolecule. The
first group possesses repetitive structural motifs (collagen, hyaluronan, decorin, and
biglycan), while the second group possesses a modular domain structure (versican,
thrombospondin, fibronectin, osteonectin, and tenascin). In contrast, the structural motifs
that convey functionality of the third group (MGP, osteopontin, BSP, and osteocalcin) are
not as well defined.
1.2.1 Bone matrix proteins with repetitive structure
The major organic component of the bone extracellular matrix is type I collagen,
accounting for up to 90% of the organic matrix. This interstitial, fibril-forming substance
is composed of trimers of two a 1(1) chains and one a2(I) chain. The repetitive motif GlyX-Y, where X and Y are often proline and its hydroxylated derivative, enables the
formation of stable triple helices. The molecular form of collagen secreted into the
extracellular matrix is procollagen, where the three a chains possess amino and carboxylterminal polypeptide extensions. Collagen fibril formation occurs following cellular
secretion and enzymatic removal of the noncollagenous N- and C-terminal extensions.
Procollagen processing is influenced by posttranslational modifications (hydroxylation of
lysyl and prolyl residues and glycosylation) and the binding of other matrix components
such as proteoglycans (Brown et al, 1989; Fessler et al, 1978; Vogel et al, 1984).
Mutations in type I collagen are also associated in vitro with alterations in the levels of
other bone matrix components, with some components being reduced (osteonectin,
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versican, decorin, and biglycan) and others elevated (hyaluronan, fibronectin, and
thrombospondin) in the matrix (Fedarko etal., 1992; 1995). Normal collagen
metabolism appears to play a role not only in structural integrity but also in cellular
feedback and bone cell proliferation/differentiation (Celic etal., 1998; Fedarko etal,
1996; Shi etal., 1996).
Hyaluronan or hyaluronic acid is found in bone (Oohira et al, 1989), is
synthesized by bone cells in culture, and has been proposed to capture space for
subsequent matrix deposition (Fedarko et al, 1990; Fisher et al., 1985). Hyaluronan is a
component of immature bone matrix, and its increased levels in 01 bone matrix are
consistent with the early, immature bone matrix, being less structurally rigid than the
mature, highly collagenous matrices. CD44, which is thought to be a cell surface
receptor for hyaluronan (Culty et a l, 1994), has been colocalized with hyaluronan on
osteoclasts, osteoblasts, and osteocytes (Noonan et a l, 1996).
Proteoglycans comprise a family of molecules that possess a core protein to which
one or more glycosaminoglycan chains are covalently attached. Decorin and biglycan are
interstitial proteoglycans found in many connective tissues, including bone (Fisher, 1985;
Almond et al., 1998). Decorin binds to the collagen fibrils (Weber et a l, 1996), while
biglycan is found in pericellular areas, including that of osteoblasts and osteocytes
(Fleischmajer et a l, 1991). The small proteoglycans may act as matrix organizers,
orienting and ordering the collagen fibrils with the protein portion binding to collagen
fibrils at specific sites and the glycosaminoglycan chains aggregating to hold the proteins,
and the collagen fibrils, at defined distances from each other (Bianco et al., 1990).
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Studies involving in vitro assays have shown that decorin inhibits the growth of collagen
fibrils (Brown etal., 1989; Vogel etal., 1984).
1.2.2 Modular domain proteins
Human bone cells produce a large chondroitin sulfate proteoglycan that is
versican-like (Fedarko et al., 1990). Although the exact function of bone versican is not
known, it has been proposed to act as a space filler in fetal and very young bone, to be
replaced by osteoid during later development (Fisher, 1985). This versican-like
proteoglycan can bind hyaluronan (Fedarko et al., 1990). Its biosynthetic level is
elevated in fetal and neonatal osteoblast-like cells and decreases with increasing donor
age (Fedarko et al., 1992).
Thrombospondins and fibronectin exemplify proteins found in bone that are
composed of various combinations and amounts of modular structures. In addition, they
contain the arginine-glycine-aspartate (RGD) cell attachment consensus sequence and are
believed to play a role in cell-matrix adhesion via binding to integrin receptors on the
cells surface (Gehron et al., 1987). Thrombospondin is synthesized by osteoblastic cells
(Asch et al., 1989). The various isoforms are expressed at different anatomical sites at
different times in bone (Gehron et al., 1989; Grzesik et a l, 1994; Tooney et al., 1998).
Fibronectin has the capacity to modulate cell migration, cell attachment, and matrix
organization. It contains binding domains for fibrin/heparin, gelatin/collagen, and cell
surfaces. Fibronectin is synthesized by and maintained around osteoblasts during
osteogenesis (Mould etal., 1990). In early bone formation, osteoblasts depend on
fibronectin for differentiation signals, while at later stages, the cells depend on
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fibronectin for survival, becoming apoptotic when antifibronectin antibodies are used to
block cellular interactions (Weiss etal., 1981).
Osteonectin (also termed secreted protein, acidic and rich in cysteine (SPARC)) is
a Ca2+-binding glycoprotein found in many connective tissues, though relatively high
concentrations are present in bone (Globus etal., 1998). Osteonectin binds to calcium,
hydroxyapatite, and collagen and, therefore, was originally hypothesized to be involved
in mineralization of bone (Globus et al., 1998). Osteonectin expression levels may be
related to rapid cell proliferation, matrix remodeling, and epithelial-mesenchymal
interactions (Raines etal., 1992; Holland etal., 1987; Tremble etal., 1993).
Tenascin (also known as hexabrachion and cytotactin) comprises an extracellular
matrix family of glycoproteins and is involved in developmental processes such as
morphogenetic cell migration and organogenesis. Tenascin is present in developing
cartilage and bone, localizing to the condensing mesenchyme of osteogenic cells invading
the cartilage (Seiffert et al., 1998). It is not detectable in mature bone matrix but is
present on periosteal and endosteal surfaces. Tenascin inhibits chondrocyte attachment to
fibronectin and by modulating fibronectin-cell interactions may affect cell rounding and
condensation (Seiffert et al, 1998).
1.2.3 Structureless matrix proteins
The RGD-containing sialoproteins osteopontin and bone sialoprotein (BSP) are
produced by osteogenic cells that are reaching maturity, and their deposition leads to the
first detectable mineralized matrix (Kessler et al., 1996). Osteopontin has an acidic
amino terminus with a polyaspartic acid sequence. Similar to BSP, osteopontin has
sequences for serine phosphorylation, N-linked oligosaccharide attachment, and tyrosine
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sulfation. The RGD is located in the carboxy-terminal region and is flanked by a
thrombin cleavage site. Immunolocolization of osteopontin revealed the highest density
of gold particles associated with electron-dense organic material (Weber et al., 1997).
Osteopontin is a potent inhibitor of hydroxyapatite formation (Chen et al, 1994).
BSP (along with osteocalcin) is considered a defining noncollagenous protein
marker of the mature osteoblast phenotype. BSP is expressed at late stages of
osteoblastic differentiation and has been localized to the sites of earliest mineral
deposition (Flores etal., 1992; Bianco et al, 1991; 1993). Osteocalcin comprises 10% to
20% of the noncollagenous proteins in bone, depending on developmental age and the
species. Levels of osteocalcin are low at early stages of bone formation and increase with
increasing age. The function of osteocalcin may be to inhibit mineralization since
osteocalcin blocks hydroxyapatite crytal growth in solution (Luo et al, 1995). It has also
been suggested that osteocalcin may function in bone resorption rather than formation
(Price et al, 1982). Target disruption of the osteocalcin gene in mice yielded a
phenotype of increased bone mass and strength suggesting that this small protein
normally inhibits bone growth and promotes bone resorption (Lian et a l, 1986).
1.3 Bone formation and bone healing
There are three basic principles responsible for enhancement of bone healing and
bone formation: (1) osteoinduction, (2) osteoconduction, and (3) osteogenesis.
1.3.1 Osteoinduction
In addition to the differentiated bone cells (osteoblasts, osteoclasts, and
osteocytes), bone and adjacent tissues contain a number of undifferentiated cells. These
undifferentiated cells are important for proper bone healing or anchorage of an implant,
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since they can be recruited to form osteoprogenitor cells and develop into differentiated
bone cells (Young, 1963). Osteoinduction is the process by which immature cells are
recruited and stimulated to develop into the bone-forming cell lineage. The classical
research describing bone induction dates back to Urist’s study in the 1965 (Urist, 1965).
Demineralized bone was used as an osteoinductive agent. Later, a soluble glycoprotein
was isolated as the osteoinductive agent called BMP (Urist e ta l, 1979). BMPs are
naturally released in response to trauma and are the only known inductive agents (Lind,
1996).
1.3.2 Osteoconduction
Osteoconduction is a process that supports the ingrowth of capillaries,
perivascular tissues, and osteoprogenitor cells from the recipient host bed into the bone
conductive material or implanted graft. Normal osteoblastic or osteoblast-like cells have
the ability to form bone on an appropriate surface. Bone growth on an implant surface
depends on the action of differentiated bone cells. These cells may originate either in
pre-existing preosteoblasts or osteoblasts that are activated by trauma or in cells recruited
from primitive mesenchymal cells by osteoinduction (Frost, 1989). The use of allogenic
bone grafts and other processed bone graft materials serves mainly as bone conductive
material.
1.3.3 Osteogenesis
Osteogenesis is the synthesis of new bone by surviving preosteoblasts and
osteoblasts within a bone autograft. The use of naturally-occuring materials, such as
autogenous or allogenic bone grafts or autogenous bone marrow grafts, to induce bone
formation and enhance fracture healing is considered to be osteogenic method. Ceramics,
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like calcium phosphate ceramics and glass ceramics, have osteoconductive properties, but
are hypothesized to stimulate osteogenesis by releasing non-organic mineral-ions, which
activates cellular processes during bone formation and healing (Teti ei al,, 1991). Bone
matrix is a source for growth factors that participate in activation and maintenance of
cellular processes during bone formation and healing. Some of these growth factors have
been shown to be able to accelerate bone formation and bone healing when applied
locally to both intact and healing bone tissue.

2. BONE MORPHOGENETIC PROTEINS
2.1 Biochemistry of bone morphogenetic proteins
BMPs are extractable from bone matrix with chaotropic agents such as 4 M
guanidine hydrochloride, 8 M urea, or 1% sodium dodecyl sulfate. Proteins with
comparable bioactivity refer either to recombinant or to partially or highly purified
proteins. The quantity of human BMPs in bone matrix is small, less than 1 pg/kg. It is
difficult to purify human BMPs to homogeneity because it forms insoluble aggregates
with itself and with other noncollagenous proteins in aqueous media. The isolation of
BMPs from cortical bone involves disassembling the densely packed structure of cortical
bone matrix. BMPs are so much less abundant in cancellous than in cortical bone that
only the diaphysis is used for chemical extraction of the BMPs (Urist, 1989).
All of the BMPs are members of the TGF-p superfamily of genes (Wozney, 1998;
Reddi, 1998; Sakou, 1998). This superfamily currently includes approximately 45 genes.
Members have been identified in most species including human and mouse, as well as
Drosophila, Xenopus, zebrafish and Caenorhabditis elegans. The structure of the
proteins of this superfamily is shown in Figure 1. Each of the proteins is produced as a
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N-terminal signal sequence, a prodomain and a mature domain at the carboxyl terminus.
The structural hallmark of this superfamily is a highly conserved 7 cysteine motif in the
mature domain. This domain also contains a relatively short amino terminal extension
that exhibits considerably more evolutionary divergence. The BMP family is the largest
subgroup in the TGF-p superfamily of molecules. The original characteristic of this
family was the ability of its members to induce new bone formation. However, not all
members in this family have demonstrated this activity.
Protein sequence characterization was the primary goal in the early discovery
research. Since only microgram amounts were available, success was achieved with
much difficulty. Multiple proteases were used to cleave the osteoinductive preparations
and micromethods were necessary for isolation of the peptides. Oligonucleotide probes
based on peptide sequences from these preparations were constructed and used to screen
human cDNA libraries. Several genes were identified, including one that was named OP1 and another that had been named BMP-2. Using these data as well as published data on
other BMPs, the 18-kDa subunit of the bovine osteoinductive preparation was identified
as the bovine equivalent of mature human OP-1, whereas the 16-kDa subunit was the
bovine equivalent of mature BMP-2.
Alignment of protein sequences in the cysteine domains reveals striking sequence
similarities and differences among the superfamily members. Table 1 demonstrates the
alignment calculated as percent of identical amino acid residues and compares OPl/BMP-7 to the other members (Griffith et al., 1996). The comparison demonstrates the
different family groupings, including, the BMP, the activin (inhibin) and the TGF-p
families. When compared to other BMPs, OP-l/BMP-7 is most closely related by
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Table 1. Comparison of representative TGF-P superfamily members: percent identity in
7 cysteine region

Family member

OP-l/BMP-7

Percent

100

Family member

Percent

GDF-1

45

BMP-5

88

SCREW

47

BMP-6

87

BMP-3B

42

BMP-8

74

BMP-3

42

BMP-8B

67

NODAL

41

60A

69

InhibinpA

43

UNIVTN

63

InliibinfB

38

BMP-2

60

InhibinpC

39

BMP-4

58

TGF-P4

38

dpp

58

TGF-P5

37

Vg-1

57

TGF-P 1

35

GDF-6

53

TGF-p3

37

GDF-7

53

TGF-p2

36

GDF-5

51

BMP-11

36

BMP-9

51

GDF-9

30

DORS ALIN

49

MIS

26

BMP-10

47

GDNF

22

GDF-3

49
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sequence to BMP-5 and BMP-6 with 88% and 87% amino acid sequence identity,
respectively, in the cysteine rich C-terminus. OP-1 is more distantly related to BMP-2
and BMP-4, having 60 and 58% identity, respectively. GDF-5, another BMP that has
been extensively evaluated, has even less similarity, showing 51% identity. BMP-3 is not
osteoinductive and, in fact, is more distant having 42% identity. The TGF-(3s themselves
are quite distant from most BMPs and do not exhibit bone inductive activity. Many of
the newer proteins in the list have not yet been expressed as recombinant proteins and
thus it is not known if they possess osteoinductive activity. Species comparisons show a
strong evolutionary conservation. For example, there is a 98% identity in amino acid
sequences in OP-1 between the human and mouse genes in the conserved mature domain.
The members of the TGF-p superfamily are signaling molecules that are
responsible for specific morphogenetic events involved in tissue and organ development.
A number of the members of this superfamily have been identified based on tissuespecific functional assays and molecular cloning approaches in various developmental
systems. The decapentaplegic gene, DPP, and the 60-A gene are responsible for proper
development of Drosophila melanogaster embryos. In Xenopus laevis, vegetal polederived transcripts, Vgr-1, and activins have been demonstrated to play a critical role in
mesoderm induction. In addition, other members of the TGF-P superfamily include:
Mullerian inhibiting substance (MIS), which causes regression of the Mullerian duct in
the development of the male reproductive tract; inhibins and activins, which act together
to regulate the release of follicle-stimulating hormone in the pituitary gland; and growth
and differentiation factors (GDFs), which are thought to be involved in many aspects of
tissue morphogenesis.
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Expression of recombinant forms of the early BMPs was accomplished using
mammalian cell lines, most particularly CHO cells (Sampath et a l, 1992; Wang et al.
1990). With this expression system, the BMPs are produced and properly refolded inside
the cells and then secreted into the media in an active form. The BMPs are then purified
from the media and characterized. Preparations of both OP-1 and BMP-2 used in clinical
testing and currently in various stages of the regulatory approval process were produced
by this methodology. However, more recently several BMPs have been produced in
bacterial cells. Recombinant preparations of GDF-5, 6, and 7 have been produced in
active form from Escherichia coli (Erlacher et al., 1998; Spiro et a l, 2000). With this
expression system, the BMPs are produced in a randomly folded state inside the cells and
after lysing the cells, the BMPs are purified and refolded into the proper conformation.
BMP-2 has also been successfully produced in E. coli (Scheufler et al., 1999). On the
other hand, OP-1 has been extensively evaluated in E. coli expression systems but
appears to be a more formidable refolding challenge and only small amounts of active
protein have been produced. Other expression systems such as yeast, plants and
transgenic animals have not been reported for expression of BMPs.
2.2 Structure of bone morphogenetic proteins
As first described for TGF-P, members of the BMP family of proteins are
synthesized as large precursors that are approximately three times larger than the mature
protein and are eventually proteolytically processed to yield mature disulfide-linked
dimers (Jones e ta l, 1994). The expression and processing has been extensively
examined for OP-l/BMP-7. The OP-1 gene predicts a polypeptide of 431 amino acids
with a 29 amino acid signal sequence. Residues 293 through 431 comprise the mature
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domain and residues 29 through 292 comprise the prodomain. OP-1 is initially
synthesized in the cell as a monomeric 50 kDa pro-protein that is dimerized,
glycosylated, and then proteolytically cleaved at the Arg-Xaa-Xaa-Arg maturation site in
an acidic cellular compartment before secretion into the medium. Of the four potential
N-linked glycosylation sites two are used, one in the mature domain and one in the pro
domain. Secreted OP-1 demonstrates an apparent molecular weight of 110-120 kDa,
indicating that after proteolytic processing the two pro-domains remain non-covalently
associated with the disulfide linked mature. During the purification procedure for mature
OP-1/BMP-7, the prodomain is normally separated from the complex by the use of
dissociating conditions. However, the intact complex can be purified in the absence of
these agents and has been characterized. This purified complex is termed soluble or
proOP-1 and is significantly more soluble in physiological buffers than the mature OP-1.
The function of the prodomain has not been elucidated. However, in addition to its
presumed role in protein folding and transport, the prodomain may participate in tissue
targeting or receptor specificity.
The crystal structure has been reported for the mature dimers of OP-l/BMP-7 and
BMP-2. The structure to 2.8 A° resolution has shown that OP-l/BMP-7 is in a “hand”
structure consisting of two fingers of antiparallel beta strands and an alpha helical region
at the heel of the palm (Griffith et a l, 1996). The central core of the hand or palm is the
site of a threaded ring structure created by the internal disulfide bonds also known as the
cysteine knot. An intermolecular disulfide bond in this “palm” region forms the dimer.
Envisioning a handshake provides a conceptual picture of this dimer interaction. The
three-dimensional structure to 2.7 A0 has recently been published for the BMP-2
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molecule and shown to be very similar to that of OP-1 (Scheufler et a l, 1999). Most
recently, the crystal structure of a BMP-2: BMPR-1A receptor ectodomain complex was
solved (Kirsch et a l, 2000). This data revealed a hydrophobic area of the type 1 receptor
that fit into a hydrophobic pocket composed of residues of both BMP-2 monomers.
2.3 BMP receptors and their signaling
Like other members of the TGF-p family, BMPs are multifunctional proteins with
effects on cell types not related to bone formation, e.g. epithelial cells, monocytes and
neuronal cells (Cunningham et al., 1992; Hogan, 1996). In addition, BMPs are expressed
not only in skeletal tissue, but also in many soft tissues. Consistent with these results,
phenotypes of mice with mutated BMP genes revealed that they are multifunctional
proteins that possess distinct roles in bone formation and many other morphogenic
processes as shown in tables 2 and 3. Interestingly, several different mouse and human
skeletal disorders (for example, short ear and brachipodism) are caused by a null
mutation in BMP-5 (Kingsley e ta l, 1992) and GDF-5 (Storm et al., 1994), respectively.
Double muscle cattle were found to have mutations in GDF-8 (McPherron et al., 1997).
Hunter-Thompson type chondrodysplasia has been linked to mutations in human
cartilage-derived morphogenetic protein (Thomas et al, 1996).
BMPs elicit their cellular effects by inducing specific heteromeric complexes of
two related serine/threonine kinase receptors, type I receptor and type II receptor
(Massague, 1998; Heldin et a l, 1997). Among the TGF-p family of receptors, the
cDNAs encoding mouse activin and human TGF-P type II receptor were isolated first by
an expression cloning strategy (Mathews et a l, 1991; Lin et a l, 1992). Both receptor
types contain glycosylated cysteine-rich extracellular ligand-binding domains, short
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Table 2. Phenotypes of organisms with disruption of genes for BMPs

Mutated gene

BMP-2

Phenotype

Embryonic death. Defects in amnion/chorion
formation and cardiac development. (Zhang et al., 1996)

BMP-3

Viable. Increased bone mass. (Daluiski et al., 2001)

BMP-4

Embryonic death. Block of mesoderm formation. (Winnier et al., 1995)

BMP-5

Viable. Skeletal abnormalities, short ear, brachypodism. (Kingsley et al., 1992)

BMP-6

Viable. Delay in developing sternum ossification. (Solloway et al., 1998)

BMP-7/OP-1

Perinatal lethality. Severe defects in kidney and eyes. (Luo et al., 1995)
Abnormalities of rib cage, skull and hindlimbs. (Dudley etal., 1995)

BMP5/7

Embryonic death. Retarded heart development. (Solloway et al., 1999)

BMP-8B

Viable. Defects in spermatogenesis. (Zhao et al., 1996)

BMP-15

Viable. Increased ovulation rate leading to twins and triple

(GDF9B)

births in heterozygotes and infertility in homozygotes. (Galloway et al., 2000)

GDF-5

Viable. Skeletal abnormalities, short ear, brachypodism. (Storm etal., 1994)

GDF-8

Viable. Increased skeletal muscle mass and body size. (McPherron etal., 1997)
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Table 3. Phenotypes of organisms with disruption of genes for BMP receptors and
downstream Smads

Mutated gene

Phenotype

Receptors
ActR-IA/ALK-2

Embryonic death. Block of mesoderm formation. (Gu et al., 1999)

BMPR-IA/ALK3

Embryonic death. Block of mesoderm formation. (Mishina et al., 1995)

BMPR-IB/ALK6

Viable. Defects in limb development. (Yi et al., 2000)

BMPR-n

Embryonic death. Block of mesoderm formation. (Beppu et al., 2000)

ActR-nA &

Embryonic death. Arrest at the egg cylinder stage

ActR-IIB

and block of mesoderm formation. (Song et al., 1999)

Smads
Smadl

Embryonic death. Defects in allantois formation. (Lechleider et al.)

Smad4

Embryonic death. Block of mesoderm formation. (Shard et al., 1998)

Smad5

Embryonic death. Defects in angiogenesis. (Chang et al., 1999)
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transmembrane domains and intracellular serine-threonine kinase domains (Massague,
1998; Heldin et a l, 1997). A shared feature for type I receptors is that they have a
glycine/serine residue-rich stretch in the juxtamembrane region, which is essential for
type I receptor activation (Wrana et a l, 1994). Three mammalian BMPR-Is have been
described to date (ten Dijke et al., 1994; Koenig et al., 1994), activin receptor-like kinase
(ALK)2, BMPR-IA (also termed ALK3), and BMPR-IB (also termed ALK6). Initially,
ALK2 was referred to as a type I receptor for TGF-P (Miettinen et al., 1994), or activin
(ActR-I) (Attisano et a l, 1993), but recent studies suggest that ALK2 is very important in
BMP signaling (Koenig e ta l, 1994; Macias-Silva et al., 1998; Armes e ta l, 1997).
Different BMPs bind with different affinity to the type I receptors. For example, BMP-4
binds preferentially to BMPR-A and -IB (ten Dijke et al., 1994), BMP-7 binds with
higher affinity to ALK2 and BMPR-IB than to BMPR-IA (ten Dijke et a l, 1994), and
GDF-5 binds preferentially to BMPR-IB, when compared with other type I receptors
(Nishitoh et a l, 1996). Functional importance of BMPR-Is in bone formation was shown
by the induction of chondroblast and osteoblast differentiation upon ectopic expression of
mutant constitutively active BMPR-Is in mesenchymal precursor cells, and by
observations that overexpression of dominant negative BMPR-Is interfered with BMPinduced osteoblast differentiation (Akiyama et al., 1997; Namiki et a l, 1997; Chen et al.,
1998; Fujii et al., 1999).
BMP type I and type II receptors have been found to be critically important for
embryogenesis (Table 3) (Goumans et a l, 2000). Mice lacking ALK3 and BMPR-II are
lethal due to absence of mesodermal development (Beppu et a l, 2000; Mshina et al.,
1995) and have a phenotype similar to BMP-4 knockout mice (Winnier et a l, 1995).
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ALK2-deficient embryos are much smaller than their normal littermates, and lack a
morphologically discernible primitive streak and die prior to or during early gastrulation
(Gu et a l, 1999). ALK6-deficient mice are viable and exhibit mainly appendicular
skeleton defects (Yi et a l, 2000). Mice lacking ActR-II or ActR-HB are viable and were
found to have a milder phenotype compared to a deficiency of one of their ligands. Some
of ActR-II-deficient animals had mandibular hypoplasia and other skeletal and facial
abnormalities (Matzuk et al, 1995). ActR-IIB knockout mice showed cardiac defects,
abnormal anteroposterior and left-right body axis patterning (Oh et a l, 1997). However,
ActR-II and ActR-IIB double-knockout homozygous showed strong lethal embryonic
abnormalities; these mice were growth arrested at the egg cylinder stage and did not form
mesoderm (Song et al., 1999). The stronger phenotype in the double knockout versus the
single knockouts suggests a functional redundancy for ActR-II and ActR-IIB in the
mouse.
BMPs exert their effects through complex formation with a heteromeric receptor
complex. The complex consists of two type I and two type II polypeptides which are
transmembrane serine/threonine kinases. The intracellular signaling pathways that are
induced by the serine/threonine kinase receptors involve a family of signaling molecules
called Smad proteins. At present, eight different Smad proteins have been identified in
mammals. They can be divided into three subclasses: R-Smads (receptor-activated
Smads), Co-Smads (common partner Smads), and anti-Smads (inhibitory Smads). Upon
BMP receptor activation R-Smads (Smads 1, 5, and 8) are phosphorylated by the
activated BMP type I receptor (Massague, 1998; Heldin et a l, 1997). Activated RSmads can form a heteromeric complex with Co-Smad (Smad4) (Lagna et a l, 1996) and
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translocate into the nucleus. Within the nucleus, R-Smads/Co-Smad complexes can
directly bind to specific sequences in the promoters of BMP target genes and regulate the
transcription of those genes (Massague et a l, 2000; ten Dijke et al., 2000).
Gene disruption of Smad genes in mice has revealed specific and developmental
functions of Smads that are implicated in BMP signaling. Whereas mice lacking Smadl,
Smad4, or Smad5 are developmentally arrested, Smad6 mice make it to term as
summarized in table 3 (Goumans et al., 2000). To study the role of Smads in cartilage
and bone formation, conditional knockouts in mesenchymal precursor cells and
osteoblasts are eagerly awaited.
2.4 BMP localization
Although BMPs were originally isolated and identified from bone, it was soon
discovered by a variety of studies that BMPs are expressed in most other tissues of the
human body. Expression has been found not only in many adult tissues, but also
throughout embryonic development (Wozney, 1998; Hogan, 1996). During
embryogenesis BMPs serve as important inductive signals for tissue development and
have been shown to have a key role in development of the musculoskeletal system, the
nervous system, the heart, kidney, skin, eyes, and teeth. After birth, the BMPs play roles
in tissue repair and regeneration. Many analytical procedures have been utilized to
localized OP-1. The first indication that OP-1 had a more widespread localization than
bone occurred when OP-1 cDNA was found in a cDNA library generated from
hippocampus (Ozkaynak et al, 1990). Subsequently, the mRNA was extracted from a
variety of adult mouse tissues and evaluated for the presence of OP-1 mRNA (Ozkaynak
et al., 1991; Ozkaynak et al, 1992). Large amounts of OP-1 mRNA were found in the
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kidney and significant amounts were found in the bladder, adrenal tissue, brain, and
calvaria. No detectable OP-1 mRNA was found in the heart and liver. Mouse embryos
were also evaluated and found to contain OP-1 mRNA in multiple organs at levels that
varied depending upon the time after conception. In gene knockout studies, mice lacking
the OP-1 gene displayed severe defects in the developing kidney and eye and appeared
polydactyl (Karsenty etal., 1996). These studies clearly demonstrated that the absence of
OP-1 disrupts the cellular interactions required for the growth and development of these
organs. Finally immunolocalization studies have shown that the OP-1 protein is also
present in multiple tissues in both adult animals and during embryonic development.
2.5 Biological activities of bone morphogenetic proteins
The biological activities of BMPs have been evaluated in vivo using a variety of
animal models and in vitro using a variety of cell lines (Azari et a l, 2001; Schmitt et al,
1999). Because of their discovery in bone, most of these studies have been done using
bone cells and bone defect animal models. Related tissues such as cartilage and other
hard tissues such as dentin have also been examined. More recently the biological
activities are being evaluated in soft tissues, particularly brain, kidney, and muscle.
The rat subcutaneous bone formation assay has been the standard method used to
evaluate the osteoinductive potential of BMPs. Implantation of purified recombinant
BMP with bone collagen matrix in subcutaneous sites in rats induces a sequence of
cellular events that results in the formation of new bone complete with bone marrow
elements (Sampath et a l, 1994). More recently the in vivo athymic mouse bioassay and
the in vitro bioassay using human periosteal (HPO) cells have been utilized to assess the
osteoinductivity of human demineralized bone matrix (Zhang et al., 1997). During the
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osteoinductive process the first step is the recruitment by the BMP of nearby
mesenchymal stem cells into the collagen matrix. The BMP stimulates the stem cells to
proliferate and then triggers their differentiation into chondrocytes in 5 to 7 days.
Cartilage is formed and on capillary invasion, the chondrocytes hypertrophy, become
calcified, and osteoblasts appear in the implant site. Newly formed bone is present in 9 to
12 days. Subsequently, the bone is remodeled extensively and becomes occupied by
ossicles filled with bone marrow elements in 14 to 21 days. This cellular process is
referred to as endochondral bone formation. Osteoinductive BMPs are also observed to
form bone by intramembraneous bone formation whereby the BMP triggers the
mesenchymal cells to differentiate directly to osteoblasts and thus bypass the cartilage
stage.
The critical activity of implanted BMPs during the bone formation process occurs
at the beginning of the biological cascade. These activities involve the interactions with
the mesenchymal cells including chymotaxis, proliferation and differentiation into bone
and/or cartilage cells. The subsequent steps appear to rely on the local induction of a
range of factors, including other BMPs. OP-1 has recently been shown to induce
numerous growth factors and multiple BMPs during the bone induction process (Patel et
al., 2001). Additional support for the action of OP-1 throughout the bone formation
process is also provided by in vitro studies (Asahina et al., 1993, 1996; Cheifetz et al.,
1996; Kitten et al., 1995; knutsen et al., 1993; Maliakal et al., 1994). These data have
demonstrated that OP-1 has multiple chondrogenic effects. This protein can induce the
chondrogenic phenotype in chondrocyte precursor cells and induce chondrogenesis in
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non-cartilage stem cells. OP-1 also promotes re-expression of chondrocyte phenotype by
dedifferentiated articular chondrocytes and enhances mature chondrocyte characteristics
in normal articular chondrocytes.
To date many studies have been published evaluating the efficacy ofBMPs in
conjunction with matrix materials for local repair of bone defects (Pecina et al, 2001).
These include most long bones, various cranialfacial bones and the spinal column. For
the most part these studies have utilized either OP-1 or BMP-2 but recent studies have
also examined GDF-5 (Spiro et al., 2000). In general, the BMPs have been shown to be
highly efficacious in repairing bones in many animal species, including rat, rabbit, dog,
sheep, goat, monkey and baboon. More recently OP-1 and BMP-2 have also been shown
to be efficacious in initial testing in humans (Fiedlaender et al., 2001; Geesink et al,
1999; Groenveld e ta l, 2000; Riedel et al., 1999).
Cartilage is observed as an intermediate step during the BMP-induced bone
induction process. Furthermore in vitro studies have demonstrated that BMPs can
promote chondrogenic differentiation, maturation, and maintenance of chondrocyte
phenotype and BMPs have been localized to cartilage (Chubinskaya et al., 2000). These
observations suggested that BMPs might be useful for healing cartilage. Studies have
been reported evaluating BMPs in in vivo models of both osteochondral and chondral
defects. Both OP-1 and BMP-2 formulated with collagen have been evaluated in
osteochondral defects and shown to be efficacious (Cook et a l, 1996; Sellers et al., 1997,
2000). These studies have demonstrated that the BMPs can improve both the bone and
cartilage healing in the defects, but the repair appears to be variable among species and
the specific type and stability of the cartilage has not fully been evaluated. In one sheep
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study using a chondral defect, OP-1 was shown to induce substantial healing (Jelic et al.,
2001). In this model which used mini-osmotic pumps to slowly deliver the OP-1 into the
articular joint, no healing was observed in the control defects.
Brain tissue has been one of the first non-bone tissues investigated for the
biological activities of BMPs (Helm etal., 2000). In vitro studies using OP-1 have
demonstrated that this BMP increased expression of the adrenergic phenotype in neural
crest cells and OP-1 regulated expression of LI and neural cell adhesion molecules in a
neural cell line. In further studies it was discovered that OP-1 selectively induces
dendritic growth in cultured rat neuron and the dendrites correctly segregate, modify
cytoskeletal and membrane proteins, and form synaptic contacts of appropriate polarity
(Wither et al., 2000). Based on these observations OP-1 was evaluated in vivo for the
repair of nerve tissue in stroke models. In rat models of cerebral hypoxial ischemia OP-1
was injected intracisternally into the brain and shown to protect against damage, as well
as to facilitate the recovery from damage caused by experimental stroke (Liu et al.,
2001 ).

The biological activities ofBMPs have also been evaluated using the kidney
(Reddi, 2000). This organ has been identified as the major site for synthesis of OP-1
during embryonic development as well as in adulthood. In addition, numerous in vitro
studies have suggested that OP-1 is required for metanephric mesenchyme differentiation
and can affect kidney cells in culture. The results from both chronic and acute disease
models in rats have demonstrated that intravenous administration of OP-1 can protect
against damage as well as facilitate recovery from this damage (Vukicevic et al., 1998).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

29
3. PURPOSE OF THIS STUDY
3 .1 Establishment of quantitative in vitro assay for evaluating osteoinductivity of DBM
Previous studies have shown that the osteoinductive activity o f DBM was
predominantly attributable to BMPs present in the bone matrix (Sampath et al., 1992;
Urist et al, 1979). The osteoinductivity of DBM depends on not only the quality of
BMPs but also the quantity of BMPs in the bone matrix (Vukicevic et al., 1989; Sampath
et a l, 1992). The osteoinductive capability of DBM is a crucial quality factor that should
be taken into account prior to distribution.
Currently, there are no standard methods for determining the osteoinductivity of
demineralized bone matrices, or similar implant materials. The use of DBM in the
induction of new bone formation has been assessed using in vivo animal based and in
vitro cell culture based bioassays. In vivo animal based bioassays are expensive and take
at least 4 weeks. Although several in vitro bioassays have been utilized for assessing
osteoinductivity of DBM, the results generally require at least 7 days. Research
endeavors have been made to develop a facile and expeditious assay for detection and
quantitation of osteoinductive proteins and to correlate that with the osteoinductivity of
bone materials. The current study is designed to establish a method of assessing
osteoinductivity of DBM using quantitative in vitro bioassay. Furthermore, this study is
directed at determining the relationships between residual calcium contents and particle
size of DBM and the extractability of BMP-4 from those DBM samples. The effects of
donor age and gender on the extractability ofBMP-4 from DBM were also investigated.
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3.2 Gene expression analysis of osteogenic differentiation
Osteoblasts are specialized cells capable of producing bone matrix. The transition
from preosteoblast to mature osteoblast occurs in distinguishable stages and has been
extensively investigated. Multipotential stem cells undergo successive stages of
differentiation with decreasing proliferation potential, giving rise to committed
preosteoblasts. Subsequently, preosteoblasts differentiate into mature osteoblasts, which
deposit the necessary components to form the bone matrix that is then mineralized.
The recently development of cDNA gene expression array technique allows the
analysis of the expression levels of hundreds to thousands of genes simultaneously,
providing an effective tool for large-scale gene expression studies (Schena et al., 1996).
The current research used gene array technology to screen alterations in gene expression
during differentiation of human periosteal cells to an osteoblast like phenotype. In this
study, the expression of 96 genes in human periosteal cells in response to DBMconditioned media was examined using human osteogenesis gene array. The results
obtained from the cDNA gene expression array analysis were validated on HPO/LNSH01 cell line using RT-PCR.
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MATERIALS AND METHODS

1. DBM
Sterile human DBM, particle size ranges from 250 to 850 microns, was kindly
provided by LifeNet, Virginia Beach, Virginia. Bone, procured by LifeNet staff from
cadaver donors shortly (less than 24 hours) after death, was stored frozen at -84°C until
processed. For processing, the bone was thawed at room temperature, mechanically
crushed to remove soft tissues such as bone marrow and periosteum, ground using a
Telsa Analytical Bone Mill, sized (250-710 micron), and refrozen.

2. PREPARATION OF BONE MATRIX WITH VARIABLE RESIDUAL CALCIUM
Ground bone matrix (particle size from 250 to 850 micron) provided by LifeNet
was demineralized by exposure to 0.5 N hydrochloric acid (HC1) (100 mg DBM to 10 ml
0.5 N HC1). Demineralized bone matrices of variable calcium content were acquired by
removing bone matrix from the acid at various time intervals; i.e., 45, 90, 135, 180
minutes, and then following a prolonged demineralization process (300 minutes). The
variably demineralized bone matrices were washed, freeze dried, and stored at -80°C.
The demineralization process was performed aseptically with no additional sterilization
of the DBM before use in the bioassays.
3. PREPARATION OF DBM WITH DIFFERENT PARTICLE SIZES
Freeze dried human cortical and cancellous bone was ground by impact
fragmentation and separated using a series of variably sized sieves. Samples were
collected according to the following particle size ranges: <250 micron, 250 to 355
micron, 355 to 550 micron, 550 to 710 micron, and 710 to 850 micron. Samples were
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then exposed to 0.5 N HC1 such that solubilized calcium phosphate salts did not
neutralize the acid solution. The demineralization process was monitored by the pH of
the demineralization solution using pH meter. The pH of the demineralization solution
was approximately 2.4 at the beginning of the demineralization process due to the
buffering ability of the calcium phosphate salts being solubilized from the bone matrix.
As the demineralization process continued, the buffering ability of solubilized salts
decreased. The demineralization process was stopped when the pH of the
demineralization solution dropped to pH 1. Based on the LifeNet’s production, the
residual calcium content of DBM reached 2%.

4. QUANTITATIVE DETERMINATION OF CALCIUM
Residual calcium contents of ground bone matrix were determined using a
modification of the DMA calcium assay kit (DMA, Inc., Arlington, Texas). This DMA
calcium procedure is based on the cresolphthalein complexone reaction as modified by
Baginski (Baginski et al., 1973). In general, calcium reacts with cresolphthalein
complexone to form a colored complex that is measured spectrophotometrically at 570
nm and is proportional to the amount of calcium present. The variably demineralized
bone matrices were dissolved in 4.0 ml of 1 N HC1 at 90°C overnight. 50 pi of sample or
appropriate standard were mixed with 4.0 ml of calcium working reagent. The pH of
each mixture was approximately equivalent. Calcium working reagent was prepared by
mixing equal amounts of calcium color reagent and calcium base reagent. Calcium color
reagent contains cresolphthalein complexone and calcium base reagent comprises
diethylamine and potassium cyanide. Absorption was measured at 570 nm. Calcium
concentrations were calculated from a standard curve using known concentrations of
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DMA calcium standard. The calcium content was expressed as weight percent calcium
of bone matrix dry weight.

5. PREPARATION OF PROTEIN EXTRACTS OF DBM
DBM samples were extracted by collagenase digestion as previously described by
Jortikka (Jortikka et al., 1993). Generally, demineralized bone matrices with particle size
ranging from 250 to 850 micron were digested with type I collagenase (Sigma Chemical
Co., St. Louis) in 200 mM Tris-HCl buffer, pH 7.2 with 3 mM CaCl2, 3mM MgS04, 20
mMNaCl, 3 mM N-ethylmaleimide (NEM), 0.1 mM phenylmethanesulfonyl fluoride
(PMSF), and 0.1 mM benzamidine-HCl at 37°C for 24 hours with continuous shaking.
The mixture was then centrifuged and the supernatant dialyzed against distilled water at
4°C overnight. The dialysate was recovered and stored at -20°C until assayed for BMP
quantity.

6. GEL ELECTROPHORESIS
For gel electrophoresis, samples of DBM protein extracts were analyzed on 4 to
15% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
according to the method of Laemmli (Laemmli et al., 1970). Molecular weight standards
were also included. Following electrophoresis, gels were stained with Bio-Safe
Coomassie blue stain.

7. WESTERN BLOT ANALYSIS
To determine the presence of BMP-4 in protein extracts of DBM, samples of
protein extracts, together with rhBMP-4 (R&D Systems, Minneapolis, MN), in Laemmli
sample buffer were applied to 4 to 15% gradient gels and subjected to SDS-
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polyacrylamide gel electrophoresis. Western blot analysis was carried out after proteins
were electrophoretically transferred to PVDF membranes (Bio-Rad, Hercules, CA).
Nonspecific hybridization was blocked by incubating the membranes in PBST
(Phosphate buffered saline with 0.1% Tween-20) containing 3% blocker for 1 hour at
room temperature. The membranes were then washed three times with PBST for 5
minutes per wash and placed in PBST containing 1% BSA (Bovine serum albumin) and
mouse anti-BMP-4 monoclonal antibody (Chemicon International, Temecula, CA) at a
concentration of 1:2000 for 1 hour at room temperature. The antibody was removed and
the membranes were then washed three times in PBST and incubated in PBST with 1%
BSA and goat anti-mouse IgG conjugated with horseradish peroxidase (Bio-Rad,
Hercules, CA) at a concentration of 1:5000 for 1 hour at room temperature. Subsequently
the membranes were washed three times in PBST and poured off PBST from the
membranes and then protein bands were visualized by placing the membrane in Opti4CN (4-chloro-1-naphthol) substrate solution until the desired level of signal is attained.
The colorimetric detection was accomplished by rinsing the membrane in deionized H2 O
for 15 minutes.

8. QUANTITATIVE BMP-4 IMMUNOASSAY (ELISA)
Quantitative sandwich enzyme-linked immunosorbent assay was employed to
determine BMP-4 content in protein extracts of DBM using a commercially available kit
(R&D Systems, Minneapolis, MN; sensitivity, 1.04 pg/ml; range, 31.2 to 2,000 pg/ml).
Briefly, 200 pi of sample or appropriate standard as shown in Figure 2 were added to
each well of a 96 well-microtiter plate precoated with anti-BMP-4 monoclonal antibody
and incubated for 2 hours at room temperature. Following a wash to remove any
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unbound antibody-enzyme reagent, 200 |il of a substrate solution was added to the well
and incubated for 30 minutes at room temperature. The color development was stopped
with 50 pi of 2 N sulfuric acid and the intensity of the color was measured using a
microplate reader (Multiskan Ascent, Labsystems, Franklin, MA) at 450 nm. The
concentration of BMP-4 in sample extracts was determined by comparing the optical
density of the sample to a standard curve as illustrated in Figure 3.

9. IN VIVO ATHYMIC MOUSE BIOASSAY
Eight to ten weeks old male athymic mice were anesthetized and tranquilized with
intraperitoneal injection of sodium Phenobarbital (0.44 ml/kg, Somnifer, Richmond
Veterinary Supply Company, Richmond, Virginia) and acepromazine (1.1 mg/kg,
PromAce, Ayerst Laboratories, Inc., New York) respectively. The area of the incision
site was disinfected with 70% isopropyl alcohol and draped for sterile surgery. A 1 cm
long incision was made along the dorsal midline through the skin and subcutaneous tissue
near the gluteal region. The incision was made using a No. 10 blade (American
Scientific Products, Illinois) on a scalpel handle size 3. Blunt dissection was made
between the skin and the tissue below with small tapered scissors. The fascia of the
longissimus dorsi muscle was pulled up with forceps and incised over the implantation
sites with small pointed dressing scissors. Muscle pouches were created bilaterally within
the longissimus dorsi muscle by blunt dissection. DBM rehydrated with saline (30
minutes before surgery) was packed into the muscle pouch. The muscle pouch was
closed with sutures of 6-0 polypropylene. The skin was closed with sutures of 6-0
polypropylene and 9 mm Michael wound clips applied on top of the sutures for protecting
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Figure 2. BMP-4 standard. Recombinant human BMP-4 was used to produce a dilution series. The 2000
pg/ml standard serves as the high standard. Calibrator diluent serves as the zero standard (0 pg/ml).
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disruption of the sutures. After 4 weeks of implantation, the implants were isolated from
the muscle pouches and cleaned of excess tissue.

10. HISTOLOGICAL EVALUATION
The explants from each implantation site were fixed in 10% neutral phosphate
buffered formalin for at least 24 hours, decalcified in 10% formic acid solution,
embedded in paraffin, sectioned, and subsequently stained with hematoxylin and eosin
prior to examination by light microscopy. The areas of new bone and total bone (new
bone and implant bone) were measured using histomorphometric analysis. The
percentage of new bone formation was expressed relative to the total cross-sectional area
measured.

11. INITIATION OF HUMAN PERIOSTEAL CELL CULTURES
Periosteum from an adult female (55 years old) femur was acquired during routine
tissue procurement by LifeNet staff with consent of the next kin. The periosteum was
washed 3 times with Minimum Essential Medium Eagle (MEM, Sigma Chemical Co, St
Louis, M4526) containing 200 units/ml penicillin and 100 pg/ml streptomycin, cut into
1.0 mm x 1.0 mm pieces, and placed with the internal stratum osteogenicum layer facing
toward the surface of the T-25 flasks. The preparation was cultured in alpha-MEM
supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/ml)
/streptomycin (50 pg/ml) in a 5% CO2 incubator at 37°C. The outgrowing cells were
combined and transferred into T-75 flasks by detachment with a 0.025% trypsin and
0.05% EDTA solution and cultured in the same media and incubator. When cells reached
confluence, they were split into new T-75 flasks at ratios of 1:4.
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12. CRYOPRESERVATION OF HPO/LN-SHOl CELLS
Passages 2-4 human periosteal cells were cryopreserved to establish a cell bank.
Cells were treated with trypsin (0.025% trypsin in 0.05%EDTA solution), neutralized
with MEM supplemented with 10% FBS and sedimented by centrifugation at 1,000 rpm
for 5 minutes. Cell pellets were resuspended in freezing solution (20% FBS and 10%
DMSO in MEM) at a concentration of 1 x 106 cells/ml and 1 ml aliquots were placed into
sterile ampules. Ampules containing cells in a styrofoam box were placed into
refrigerator (4°C) for 2 hours, transferred into a freezer (-20°C) for 8 hours, a -70°C
freezer overnight, and finally transferred to -140 °C for long term storage.

13. CELL THAWING AND CULTURE
For experiment use, ampules of frozen cells were quickly removed from the
-140°C storage freezer, thaw in a 37°C water bath for 2 minutes and the cells immediately
transferred into T-75 flasks with 20 ml of MEM supplemented with 10% FBS, and put
into a 37°C, 5% C02 incubator. When cell cultures reached confluence, HPO/LN-SHOl
cells were treated with trypsin and split 1:4 into new T-75 flasks until sufficient cell
populations were obtained for experiments.

14. CULTURE OF CELLS USED IN ALKALINE PHOSPHATASE ASSAY
When appropriate numbers ofHPO/LN-SH-01 were acquired, cells were treated
with trypsin, neutralized with 10% FBS, and sedimented by centrifugation at 1,000 rpm
for 5 minutes. Cell pellets were resuspended in small volumes of MEM supplemented
with 10%FBS and pooled into one T-75 flask. Pooled cell suspensions were mixed well
by trituration and counted using a hemocytometer. Cells were seeded into T-25 flasks at
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6.25 x 105 cells per flask (or 2.5 x 104 cells/cm2). These cell cultures were maintained in
10 ml of alpha-MEM supplemented with 10% fetal bovine serum (FBS) and penicillin
(100 units/ml) /streptomycin (50 pg/ml) until reaching confluence. The alpha-MEM
medium was then changed to 10 ml of Dulbecco’s Modified Eagles’ Medium (DMEM,
Sigma Chemical Co., St. Louis, D8788) supplemented with 2% FBS. Various
concentrations of DBM condition media (DBM-CM) were added into randomly assigned
flasks immediately following changing of the medium to DMEM.

15. ALKALINE PHOSPHATASE ASSAY
Alkaline phosphatase is a membrane bound enzyme that is present in many cell
types but is most abundant in osteoblasts. Alkaline phosphatase is a specific marker of
the osteoblastic phenotype and thought to be of importance in the mineralization process
by increasing the concentration of inorganic phosphate resulting in precipitation of
calcium-phosphate crystals. The mesenchymal cell induction process typically associated
with osteoinductivity of demineralized bone materials is monitored by changes in
alkaline phosphatase activity of cells being studied. According to Zhang (Zhang et al.,
1997), nonosteoinductive (HPO) cells express low level of alkaline phosphatase activity,
whereas osteoinducing cells express high level of alkaline phosphatase activity. This
protein can be visualized by histochemical alkaline phosphatase staining assay. The
alkaline phosphatase activity can also be quantified by incubating cell lysate with pnitrophenyl-phosphate then measuring absorbance in a spectrophotometer or microplate
reader at 405 nm. This alkaline phosphatase activity assay is facile and reliable when
performed in triplicate in 96-well plates.

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

41

Alkaline phosphatase staining assay was performed using the Sigma Diagnostics
Alkaline Phosphatase kit (Catalog No.86-2, Sigma Diagnostics, Inc., St. Louis) as
directed by the manufacturer. Briefly, cell layers were rinsed with phosphate buffer
saline (PBS), fixed with citrate-acetone-formaldehyde fixative solution at room
temperature for 30 seconds, and then stained with alkaline-dye mixture at room
temperature for 15 minutes. Naphthol AS-BI alkaline solution and fast red violet B
(FRV-alkaline solution) were utilized for determining the enzyme activity. Slides were
then counterstained with hematoxylin solution, gill No. 3 and evaluated using light
microscopy.
Alkaline phosphatase activities were determined using a modification of the
procedure described by Wolfinbarger and Zheng (Wolfmbarger et al., 1993). Basically,
treated cells were quickly rinsed twice with 3 ml deionized water, scraped with a cell
scraper (Fisher Scientific, Pittsburgh, PA) in 3 ml deionized water and sonicated at 30%
intensity for 30 seconds. Next 200 pi aliquot samples were transferred to each well of a
96-well plate and were mixed with 40 pi of 100 mmol/ml p-nitrophenyl phosphate in
0.15 M 2-amino-2-methyl-1-propanol buffer, pH 10.4, and incubated for 20 minutes at
37°C. The reaction was stopped by the addition of 10 pi of 10 N NaOH into each well
and absorbance determined at 405 nm using a microplate reader (Multiskan Ascent,
Labsystems, Franklin, MA). Alkaline phosphatase activity (expressed as pmols of
converted p-nitrophenol/min) was normalized by total protein content. Protein
concentrations of the samples were determined by using the BCA protein assay (Pierce,
Rockford, IL). The Alkaline phosphatase activities were expressed as pmols of pnitrophenol/min/pg of protein).
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16. STATISTICAL ANALYSIS
The data are expressed as means with error bars representing standard error of the
mean (SEM). Analysis of variance (ANOVA) was used to determine the significant
differences among treatment groups. Tukey-type multiple comparison tests were used for
comparing means of more than two groups in one way ANOVA analyses. Correlation
between extractable BMP-4 level and osteoinductive capability of DBM was analyzed by
linear regression analysis (SPSS 10.00); A P value of less than 0.05 was considered to be
statistically significant.
17. RNA ISOLATION AND MICRO ARRAY ANALYSIS
Total cellular RNA was isolated from HPO cells on days 7 in the presence or
absence of 100 pg/ml DBM-CM using the RNeasy Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. The purity and amount of isolated RNA
were assessed by spectrophotometric measurement at 260 and 280 nm. Equal amounts of
total cellular RNA (5 pg) was reverse transcribed to cDNA at 42°C for 90 minutes in a
volume of 20 pi containing the following reagents: 3 pi GEA primer mix (Buffer A); 4 pi
5x GEA labeling buffer (Buffer BN); 1 pi RNase inhibitor (Promega, Madison, WI), 2 pi
1 mM Biotin-16-dUTP (Roche), and 50 U MMLV reverse transcriptase (Promega,
Madison, WI). After terminating the reaction by adding 2 pi lOx stop solution (Buffer
C), the biotin labeled cDNA probes were denatured by heating at 94°C for 5 minutes and
chilled quickly on ice.
Human osteogenesis GEArray Q series cDNA expression arrays (SuperArray
Bioscience, Frederick, MD) nylon membranes, containing over 96 cDNA fragments from
genes associated with bone development, were used for hybridization studies. The arrays

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

43
were prehybridized with 200 pg of the heat-denatured salmon sperm DNA (Invitrogen/
Life Technologies, Carlsbad, CA) and 2.0 ml GEAhyb hybridization solution
(SuperArray Bioscience, Frederick, MD) for 2 hours at 60°C. The denatured cDNA
probes were added to the GEAhyb hybridization solution and left to hybridize with the
array nylon membranes overnight with continuous agitation at 60°C. Washes were done
twice at 60°C in 2x SSC with 1% sodium dodecylsulfate (SDS) for 15 minutes and twice
at 60°C in 0. lx SSC with 0.5% SDS for 15 minutes with continuous agitation. The
membranes were blocked for 40 minutes by incubating with 2 ml GEA blocking solution
Q at room temperature and incubated with a 1:7500 dilution of alkaline phosphataseconjugated streptavidin for 10 minutes. Subsequently, membranes were then washed
four times in lx buffer F (SuperArray Bioscience, Frederick, MD) and rinsed twice with
lx AP-assay buffer G (SuperArray Bioscience, Frederick, MD). Visualization was
accomplished using 1.0 ml CDP-star chemiluminescent substrate (SuperArray
Bioscience, Frederick, MD) to sufficiently cover the membranes for 2 minutes at room
temperature. The membranes were placed on Kodak BioMax maximum resolution (MR)
autoradiography film (Kodak, Rochester, NY) at room temperature. Appropriately
exposed autoradiographs of the membranes were quantified by translumination of the Xray film using a scanner (Hewlett-Packard).
The image obtained using a scanner was converted into a gray scale TIFF file.
The TIFF image was then converted to numerical data by using ScanAnalyze software,
developed by Michael Eisen of Standford University. Images were gridded to locate the
spot corresponding to each gene. Following gridding, information on each spot,
including intensities, background intensities and ratios, was extracted using ScanAlyze

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited without perm ission.

44

and presented as a Microsoft Excel file. Ratios were ultimately used to determine
differentiation of gene expression. Genes with ratio number above 2 or under 0.5, i.e., 2
fold induction or repression, were selected and subjected to further analysis. The array in
this study contains pUC18 as a negative control and also contains GAPDH, cyclophilin
A, RPL13A, and P-actin as positive controls, which were averaged to create a
normalization value for each array. Each signal was normalized against the signal of a
housekeeping gene in order to compare data from two different arrays. The relative
specific intensity within each signal was calculated as the ratio of the density of each
signal in the DBM-CM treatment divided by the density of corresponding signal in the
control (without DBM-CM addition) using GEArray Analyzer software (SuperArray
Bioscience, Frederick, MD).

18. POLY (A)+ RNA PURIFICATION AND RT-PCR
Poly (A)+ RNA was isolated from HPO cells that were cultured with or without
DBM-CM for 0, 4, 7, 10, and 14 days using the QuickPrep Micro mRNA Purification Kit
following the manufacturer’s instructions (Amersham Biosciences, Piscataway, NJ). For
RT-PCR analysis, 150 ng poly (A)+ RNA was reverse transcribed to cDNA at 42°C for
60 minutes in a volume of 20 pi containing the following reagents: 0.5 mM dNTP mix;
lx ImProm-II Reaction Buffer; 6 mM MgCL; and 20 U of Recombinant RNasin
Ribonuclease Inhibitor. The reactions were then terminated at 70°C for 15 minutes.
Aliquots of the cDNA were amplified in 100 pi of a PCR reaction mixture which
contained 1 pM primer sets, lx thermophilic polymerase reaction buffer (BioRad) (lOx =
200 mM Tris-HCl, pH 8.4, and 500 mM KC1), and 5 U of iTaq DNA polymerase
(BioRad). Primers for biglycan, collagenl4Al, and GAPDH were prepared based on
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previously described sequences as follows: biglycan (sense: 5’CCCTCTCCAGGTCCATCCGC-3’ and antisense: 5’GAGCTGGGTAGGTTGGGCGGG-3 ’, Chen etal. 2002); collagenMAl (sense: 5’TGGACAGAACCAGCTACAACCATAGT-3’ and antisense: 5’GGAGACGCTGACGCCTTCGCCATCCGT-3Meirowitz etal. 2002); and GAPDH
(sense: 5’-ACCAC AGTCC ATGCC ATCAC-3 ’ and antisense: 5’TCCACCACCCTGTTGCTGTA-3 ’, Locklin et al. 2001). All primers were purchased
from Integrated DNA Technologies, Coralville, IA. Amplifications were performed in a
thermocycler. DNA amplification included an initial denaturation at 94°C for 2 minutes,
followed by 25 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 1
minute, and extension at 72°C for 2 minutes. The final cycle included 5 minutes for
extension. Aliquots of the PCR products were diluted 1:10 and then analyzed by
electrophoresis in 2% agarose gel stained with Gel star Stain (Clare Chemical Research,
Inc., Dolores, CO). PCR markers (Promega, Madison, WI) were used as molecular
weight markers. 1.2 kb Kanamycin RNA combined with oligo (dT)is primer served as a
positive control. As a negative control, PCR amplification without either RT or poly (A)+
RNA was carried out. No PCR products were obtained in these experiments for all pairs
of primers.

19. HUMAN SUBJECTS
According to the office for human research protections website,
http ://ohrp.osophs, dhhs. gov/humansubi ects/assurance the use of human tissue in this
dissertation research does not fall under their guidance. They define human subjects as a
living individual about whom an investigator (whether professional or student)

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

46
conducting research obtains data through intervention or interaction with the
individual(s), or identifiable private information. This tissue used in the dissertation
research does have consent from the donor’s family as required in LifeNet policy, POLRD-001.002.
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Table 4. Sequences of human oligonucleotide primer pairs used in RT-PCR

Gene
BGN

Sequence

Product length (bp)

(sense)
5 ’-CCCTCTCCAGGTCCATCCGC-3 ’
(antisense) 5’-GAGCTGGGTAGGTTGGGCGGG-3’

500

COL14A1 (sense)
5 ’-TGGACAGAACCAGCTACAACCATAGT-3 ’
(antisense) 5 ’-GGAGACGCTGACGCCTTCGCCATCCGT-3 ’

315

GAPDH

500

(sense)
5 ’-ACCACAGTCCATGCCATCAC-3 ’
(antisense) 5 ’-TCCACCACCCTGTTGCTGTA-3’
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RESULTS

1. QUANTITATIVE IN VITRO BIOASSAY
1.1 Presence of BMP-4 in protein extracts of DBM
The present study was undertaken to determine whether BMP could be extracted
and identified using Western blot analysis. The protein extracts of DBM were separated
on SDS-PAGE, transferred to PVDF membranes, and probed with a monoclonal antibody
directed against human BMP-4. A serial dilution of recombinant human BMP-4 served
as a positive control. Western blot analysis displayed the detection of a single band of 18
kDa that was consistent with that of BMP-4 (Figure 4). The results indicate the presence
of BMP-4 in the protein extracts of DBM. However, the levels of extractable BMP-4
were unable to be accurately quantified using Western blot analysis.
1.2 The effect of residual calcium on extractability of BMP-4
The quantitative BMP-4 in vitro assay was utilized to study the effect of residual
calcium contents on the extractability ofBMP-4 from DBM. Equivalent amounts (100
mg) of DBM with different levels of residual calcium were extracted by collagenase
digestion. Extractable BMP-4 levels were measured using BMP-4 ELISA, and the results
were compared and demonstrated in Figure 5. Results are representative of at least two
independent experiments.
As shown in Figure 5, the data from samples of bone matrix containing 18% to
0.05% residual calcium indicated that as the residual calcium level decreased, the
extractability ofBMP-4 increased. The level of extractable BMP-4 was unable to be
detected in non-demineralized bone matrix (25% residual calcium) with this BMP-4
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Figure 4. Western blot analysis of protein extracts from human demineralized bone and recombinant
human BMP-4. Extracts were prepared as delineated in Materials and Methods and then
electrophoresed on SDS-gels. After electrophoresis, protein samples were transferred to PVDF
membranes and stained with anti-BMP-4 monoclonal antibody. Lanes 1-6: rhBMP-4 64, 32, 16, 8, 4,
and 2 ng, respectively; Lane 7: protein extracts of DBM; Lane 8: protein extracts of DBM spiked with
8 ng of rhBMP-4. Results are representative of at least two independent experiments.

VO

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Relationship Between Percent Residual Calcium and BM P-4 levels
4000
3500
^

3000

«

>+
H 250)
o
eo
<3b 2000
&
j?

1500

PQ 10CX)
500

-f-

0
18-%

14.5-%

9-%

1.8-%

0.8-9

0.05-'

%Residual Calcium

Figure 5. BMP-4 levels in protein extracts of demineralized bone particles containing variable levels
of residual calcium. DBM with different levels of residual calcium were extracted and extractable
BMP-4 levels were determined using BMP-4 ELISA. The residual calcium levels were measured
using the DMA Calcium assay. Particle sizes of DBM used here were 250 to 850 microns. Data are
shown as means with error bars representing standard error of the mean (SEM) (n=3).
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ELISA (data not shown). On the other hand, the DBM demineralized to a residual
calcium content of 0.05% produced the highest level of extractable BMP-4 among the
variable residual calcium level group tested. In general, the relationship between the
residual calcium contents of 25 (non-demineralized bone) to 0.05 weight percent and the
extractability ofBMP-4 from DBM can be expressed as: Y = -359.23 X + 2198.7, (R =
0.9745), where Y is the extractable BMP-4 level of DBM and X is the residual calcium
content of DBM.
To further normalize and compare the extractability ofBMP-4 of variously
demineralized bone matrices, the percentages of the highest extractability ofBMP-4 were
calculated and compared. As illustrated in Table 5, the maximum extractability of BMP4 was accomplished by bone matrix containing 0.05% residual calcium. The 0.8%
residual calcium bone matrix achieved 73% of the maximum extractable BMP-4 level,
the 1.8% residual calcium bone matrix attained 56% of the maximum extractable BMP-4
level, the bone matrix demineralized to 9% calcium revealed 26% of the maximum
extractable BMP-4 level, the bone matrix demineralized to 14.5% calcium produced 18%
of the maximum extractable BMP-4 level, and the 18% residual calcium bone matrix
yielded 12% of the maximum extractable BMP-4 level. The non-demineralized bone
matrix did not exhibit any extractability ofBMP-4 in this assay.
ANOVA analysis indicated that there were significant differences among the
extractability ofBMP-4 from DBM with different degrees of residual calcium (P < 0.05).
Tukey-type multiple comparison test revealed that the extensively demineralized bone
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Table 5. The effect of residual calcium on the extractability ofBMP-4 in DBM

Time Percent residual calcium Extractable BMP-4 level (pg/g DBM) % of the highest level of BMP-4
0

25

0

0

45

18

419

12

90

14.5

657

18

135

9

930

26

180

1.8

1997

56

225

0.8

2593

73

300

0.05

3571

100
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matrix (0.05% calcium content) had significantly higher extractable BMP-4 level than
DBM with residual calcium contents of 0.8, 1.8, 9.0, 14.5, and 18.0% and yielded the
highest BMP-4 level in the protein extracts derived from DBM.
Generally, the residual calcium contents of DBM significantly affected
extractability ofBMP-4. Non-demineralized bone matrix did not provide for any
extractable BMP-4, and as the residual calcium content decreased the extractability of
BMP-4 of bone matrix increased. The 0.05% residual calcium bone matrix resulted in
the highest level of extractable BMP-4.
1.3 The effect of particle size on extractability ofBMP-4
The effect of particle size on extractability ofBMP-4 from DBM was evaluated
using the quantitative BMP-4 in vitro assay. Equivalent amounts (100 mg) of DBM with
different particle size were extracted by collagenase digestion. Extractable BMP-4 levels
were measured using BMP-4 ELISA.
The effects of particle size on extractability ofBMP-4 from DBM were compared
and demonstrated in Figure 6. Results are representative of at least two independent
experiments. Different particle sizes of DBM exhibited distinct effects on extractability
ofBMP-4. The effects of particle size on extractability ofBMP-4 were assessed using
BMP-4 ELISA. Demineralized bone particles in the 550 to 710 micron size range
exhibited the highest levels of extractable BMP-4 when compared to similarly
demineralized DBM of different particle size ranges. From the <250 micron particle size
range of DBM to the 550 to 710 micron particle size range of DBM, as the particle size
increased the extractability ofBMP-4 from DBM increased. Smaller particle sizes and
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Figure 6. BMP-4 levels in protein extracts of demineralized bone particles of variable particle size
ranges. DBM with different particle size ranges were extracted and extractable BMP-4 levels were
determined using BMP-4 ELISA. Data are shown as means with error bars representing standard error
of the mean (SEM) (n=3).
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larger particle sizes resulted in lower levels of extractable BMP-4, such that DBM bone
particles in the 355 to 550 micron and 710 to 850 micron particle size groups provided
for equivalent levels of extractable BMP-4. As shown in Table 6, DBM in the <250
micron bone particle size range showed extractable BMP-4 levels which approximated
64% of the highest extractable BMP-4 levels observed, and DBM in the 250 to 355
micron bone particle size range yielded extractable BMP-4 levels approximating 72% of
the highest extractable BMP-4 levels observed.
ANOVA analysis revealed that there were significant differences among the
extractable BMP-4 levels of DBM in the different bone particle size groups (P < 0.05).
Tukey-type multiple comparison test indicated that the 550 to 710 micron bone particle
size group had significantly greater extractable BMP-4 than DBM in all other bone
particle size groups tested. There were no significant differences in extractable BMP-4
levels of DBM between the <250 micron and the 250 to 355 micron, the 250 to 355
micron and the 355 to 550 micron, and the 355 to 550 micron and the 710-850 micron
bone particle size groups as displayed in Table 7.
Generally, particle size of DBM exhibited a significant effect on the extractability
ofBMP-4. Under identical conditions of demineralization the 550 to 710 micron particle
size resulted in the maximum level of extractable BMP-4. The DBM particle size 710 to
850 micron and 355 to 550 micron illustrated equivalent levels of extractable BMP-4.
The DBM particle size range <250 micron possessed the minimum level of extractable
BMP-4.
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Table 6. The effect of particle sizes on extractability ofBMP-4 in DBM (expressed as the
percentage of the highest level of extractable BMP-4)

Size (micron)

Extractable BMP-4 level (pg/g DBM)

% of the highest level of BMP-4

<250

1440

64

250-355

1632

72

355-550

1906

84

550-710

2257

100

710-850

1943

86

Table 7. Statistical analysis of the effect of particle size on extractability ofBMP-4 in
DBM. Tukey-type multiple comparison, Probability level: 0.05

Subset1 1: <250 micron2 , 250-355 micron
Subset 2: 250-355 micron, 355-550 micron
Subset 3: 355-550 micron, 710-850 micron
Subset 4: 550-710 micron

1 Subset is a term used in Tukey-type multiple comparison. There is a statistically significant difference
among the particle size groups that appear in different subsets. There is no statistically significant
difference among the particle size groups that appear in the same subset.
2 The particle size group represents the particle size group of DBM tested in the quantitative BMP-4 in
vitro assay.
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1.4 The effect of donor age on extractability ofBMP-4
Demineralized bone matrices with residual calcium levels approximately 2% were
provisioned by LifeNet. The DBM samples were classified into 3 age groups according
to the donor age as follows: 0 to 25 years of age (n=T4), 26 to 44 years of age (n=15), and
more than 45 years of age (n=T 1). As demonstrated in Figure 7, there was an agedependent decline in extractable BMP-4 level as measured by BMP-4 ELISA. DMB
from donors in the age group 0 to 25 years of age provided the maximum levels of
extractable BMP-4, 4572 pg/g of DBM. DBM from donors in the age groups of 26 to 44,
and more than 45 provided the extractable BMP-4 levels of 3383, and 3035 pg/g of
DBM, respectively, which are significantly less than the extractable BMP-4 levels
obtained from the donors in the age group 0 to 25 years of age.
1.5 Extractability ofBMP-4 as a function of male donor age
The effects of male donor age on the extractability ofBMP-4 in DBM were
expressed as levels of extractable BMP-4 as illustrated in Figure 8. The data illustrated in
Figure 8 indicate that extractability ofBMP-4 varies as a function of male donor age.
DBM from the male donors in the age group 0 to 25 years of age (n=5) resulted in the
highest levels of extractable BMP-4 (4432 pg/g of DBM). DBM from the male donors
older than 25 showed a decline in the levels of extractable BMP-4, for example, 3780
pg/g of DBM for the 26 to 44 year age group (n=10) and 3353 pg/g of DBM for the >45
year age group (n=7). However, there was no statistically significant difference in the
extractable BMP-4 among DBM samples derived from male donors.

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Relationship Between Age group and BMP-4 level

o

5500
5000
4500
4000
3500
3000 2500

T

2000
3 1 1500

1000

□ <25

□ 26-44
■ >45

j

500

0
<25

26-44

>45

Age group
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1.6 Extractability ofBMP-4 as a function of female donor age
The effects of female donor age on the extractability ofBMP-4 were examined
and the data are presented in Figure 9. The maximum levels of extractable BMP-4 were
observed in the female donors in the age group 0 to 25 years of age (n=9) (4649 pg/g of
DBM), which is the same as the corresponding male group. DBM from the female
donors in the age groups of 26 to 44 (n=5), and >45 (n=4) provided the extractable BMP4 levels of 2590, and 2479 pg/g of DBM, respectively, which are significantly lower than
the extractable BMP-4 levels obtained from the female donors in the age group 0 to 25
years of age. The data indicate that there is an age-dependent decrease in the levels of
extractable BMP-4 derived from DBM of female donors.
The results of the effects of age and gender were analyzed and are illustrated in
Table 7. DBM from the female donors in the age group 0 to 25 years of age provided the
greatest levels of extractable BMP-4 among all of the donor age groups tested (both male
and female) and was designated as 100% extractability. DBM from the male donors in
the age group 0 to 25 years of age exhibited 95% of the highest extractability. The
percentage of the highest extractability provided by DBM from other donor age and
gender groups can be put in order from large to small as the following series: DBM from
male 26 to 44 year age group (81%), DBM from male >45 year age group (72%), DBM
from female 26 to 44 year age group (56%), and DBM from female >45 year age group
(53%).

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

Relationship Between Age Group of Female and BMP-4
5500
5000
g 4500
g 4000
E 3500
3000
g 2500
* 2000 -j
| 1500

I

-t

1000
500

0
<25

26-44

>45

Age group

Figure 9. The effect of female donor age on the extractability of BMP-4 in DBM. DBM from different
donors was categorized into the age groups as described and extracted by collagenase digestion.
Extractable BMP-4 level of DBM was measured using BMP-4 ELISA and expressed as pg of BMP-4
per g of DBM. Data are shown as means with error bars representing standard error of the mean (SEM).
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Table 8. The effect of age and gender on the extractability of BMP-4 in DBM (expressed
as percentage of the highest level of extractable BMP-4)

Age Group

Extractable BMP-4 level (pg/g DBM)
Male donor Female donor

% of the highest level of BMP-4
male donor

Female donor

<25

4432

4649

95

100

26-44

3780

2590

81

56

>45

3353

2479

72

53
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1.7 Correlation of extractable BMP-4 levels of DBM and osteoinductivity
The osteoinductive potential of DBM is prominently attributed to the availability
of BMP present in DBM. Among the BMP family, BMP-4 is one of the most
osteoinductive factors and has been investigated for clinical applications. Therefore, it is
essential to investigate the relationship between the levels of extractable BMP-4 from
DBM and the osteoinductivity of that DBM in the in vivo athymic mouse bioassay. Bone
samples of 40 donors demineralized under production conditions at LifeNet were
extracted and analyzed by BMP-4 ELISA. In addition, the osteoinductivity of DBM
from the same donors quantitated by BMP-4 ELISA were assessed using the in vivo
athynic mouse bioassay. As demonstrated in Figure 10, the amounts of the extractable
BMP-4 in the protein extracts of DBM were variable among DBM samples. The
extractable BMP-4 levels ranged between 1.82 and 7.94 ng/g of DBM (mean = 3.7 ± 0.21
ng BMP-4/ g of DBM). Figure 11 illustrated that DBM samples possessing high
osteoinductivity in the nude mouse bioassay contained greater BMP-4 levels in the
protein extracts from these DBM than those DBM samples exhibiting low levels of
osteoinductivity. There was a good positive correlation between the quantitative BMP-4
in vitro assay and osteoinduction (percentage of new bone formation) determined by the
implantation of DBM in the in vivo nude mouse bioassay with a correlation coefficient of
0.74 (P < 0.001).
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BMP-4 contents in protein extracts of 40 different DBM samples were analyzed using BMP-4 ELISA.
All results are shown as means with error bars representing standard error of the mean (SEM).
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Figure 11. Correlation between extractable BMP-4 levels of DBM determined by ELISA and
percentage of new bone formation (in vivo) determined by histomorphometric analysis. A total of 40
DBM samples from 40 different donors were divided into two portions, one portion was used in the
quantitative BMP-4 in vitro assay with the second portion used in the in vivo athymic mouse bioassay.
Correlation was analyzed by the linear regression analysis (SPSS 10.00). Regression coefficient (R)
was 0.74 (P < 0.001).
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2. GENE EXPRESSION ANALYSIS OF OSTEOBLAST DIFFERENTIATION
2.1 Initiation and characterization of HPO/LN-SHOl cell line
A human periosteal cell line was acquired using the outgrowth technique from the
periosteum (Figure 12 and 13) as described in the Materials and Methods. This cell line
was established by propagation of the primary cultured periosteal cell line to approximate
passage 4 and was designated HPO/LN-SHOl, and phenotypic characteristics were
maintained over the course of this study by cryopreservation. All cells used in this study
were from this cell line. In bone repair it has been suggested that osteoblast progenitor
cells migrate from the periosteum and differentiate into osteoblast cells that in turn result
in the new bone formation (Ham and Harris, 1956).
The morphologic pattern of HPO/LN-SHOl cells in cell culture is demonstrated in
Figure 14. Cultured in the minimum essential media supplemented with 10% FBS, the
periosteal cells exhibited spindle and stellate shapes with fine homogenous cytoplasm,
typically associated with fibroblast-like cells. The most distinguishing characteristic of
the cell line is the long processes. When confluent, as shown in Figure 15, HPO/LNSHOl cells were aligned in orderly manner and displayed a regular confluent pattern
where some areas have high cell density and some areas have lower cell densities.
2.2 Ability of DBM-CM to induce alkaline phosphatase activity in HPO cells
Previous studies in our laboratory demonstrated that DBM has osteoinductive
potential in in vitro assays. However, the biochemical mechanism(s) behind this
osteoinductive process in the in vitro cell culture system remains unknown. It has been
postulated that the DBM either releases the inducing stimulus or the stimulus may be
mediated through a direct DMB-osteoprogenitor cell interaction.
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days after explantation ( x 10).

68

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

69

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 15. Confluent HPO/LN-SHOl cells in monolayer culture ( x 10). Cells were cultured in alphaMEM supplemented with 10% FBS and penicillin (100 units/ml)/streptomycin (50 pg/ml).
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To determine whether the osteoinductive proteins or other factors represent a soluble
component of DBM released and distributed into the media in vitro, conditioned media
were prepared from DBM. DBM was suspended in serum-deprived DMEM for 4 weeks
in the cold room (0-4°C). The conditioned medium was centrifuged to separate and
remove DMB and then concentrated using a 10 kDa pore size, centrifugal device
(Millipore). Next this concentrate was measured for protein concentration by using a
BCA (Bicinchoninic acid) protein assay, then aliquotted and stored at -80°C.
To assess dose dependence, various concentrations of DBM-conditioned media
(DBM-CM), 1, 10, 50, 100 pg/ml were added to separate confluent cell cultures of HPO
cells. HPO cells without DBM-CM treatment served as a control. The alkaline
phosphatase activities were assayed on day 5 after the treatment. The results are
representative of at least two independent experiments and are displayed in Figure 16.
The addition of increasing concentrations of DBM-CM enhanced alkaline phosphatase
activities ofHPO cells in a dose-dependent manner. The alkaline phosphatase activity
was maximal at the highest concentration tested (100 pg/ml). These results indicate that
there are soluble osteoinductive factors that can diffuse from the DBM and become
distributed into the media.
2.3 Morphologic and histochemical studies of the effects of DBM-CM on HPO cells
Morphologic and histochemical studies were also conducted for DBM-CM. DBMCM (100 pg/ml) was added to the confluent cell culture ofHPO cells. HPO cells without
DBM-CM treatment were used as a control. After 5 days of incubation, Cell morphology
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Figure 16. Alkaline phosphatase activity assay of DBM-CM dose response study. DBM-CM (0,1,10,
50, 100 pg/ml were added into confluent flasks of HPO/LN-SHOl cells. Alkaline phosphatase activity
were measured after 5 days of DBM-CM treatment. Data are shown as means with error bars
representing standard error of the mean (SEM) (n=3).
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was observed and alkaline phosphatase staining assay was performed. The control cells
(without DBM-CM treatment) possess a spindle shape, and there was very little
extracellular matrix as demonstrated in Figure 17. In contrast, the DBM-CM treated cells
(Figure 18) appeared shortened and flattened, and they were surrounded by extracellular
matrix. Furthermore, in the control slides, cells were stained blue (Figure 19), suggesting
low levels of alkaline phosphatase activity. On the other hand, in the DBM-CM treated
slides, a strong red and purple color appeared in all the areas (Figure 20) indicating very
high alkaline phosphatase activities. These histochemical studies confirmed that DBMCM has a strong stimulatory effect on the alkaline phosphatase activities ofHPO cells, a
very early marker of cell differentiation into the osteogenic lineage.
2.4 Gene expression profiling of HPO/LN-SHO1 cells during osteogenic differentiation
cDNA gene expression arrays are rapidly becoming the method of choice to
examine gene expression profiles in various specialized systems and to discover new
bone-related genes which may play essential roles in osteoblast development. To attain a
profile of gene expression during differentiation, total RNA was harvested from HPO
cells in the absence or presence of DBM-CM at day 7 and used as template for synthesis
of biotin labeled cDNA probes and hybridized to human osteogenesis gene arrays
containing 96 cDNA fragments. The recorded raw array images were scanned and
converted into a digital image file. The scan results were saved under TIFF format and
subsequently analyzed using a program called ScanAlyze (written by Michael Eisen,
Stanford University). Images were gridded to locate the spot corresponding to each gene
as illustrated in Figure 21. Following gridding, information on each spot, including
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Figure 17. Morphology study of human periosteal cells without DBM-CM addition ( x 10). HPO/LNSHOl cells were incubated in DMEM assay media alone for five days. Spindle-like cells with little
extracellular matrix were observed.
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Figure 18. Morphology study of the effects of DBM-CM on human periosteal cells ( x 10). HPO/LNSHOl cells were incubated with DBM-CM (100 pg/ml) and DMEM assay media for five days. Cells
retracted from some areas which are surrounded with extracellular matrix.
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intensities, background intensities and ratios, was extracted using ScanAlyze and
presented as a Microsoft Excel file. Ratios were ultimately used to determine
differentiation of gene expression. Genes with ratio number above 2 or under 0.5, i.e., 2

fold induction or repression, were selected and subjected to further analysis. Table 9 lists
the names, accession numbers, and description of genes present in the cDNA array. The
array in this study contains pUC18 as a negative control and also contains GAPDH,
cyclophilin A, RPL13A, and P-actin as positive controls, which were averaged to create a
normalization value for each array.
To ensure reproducibility of cDNA array results, the assay was repeated twice
using independent RNA samples. Figure 22 represents typical hybridization result in
which the cDNA probe derived from non-treated cells and the cDNA probe from DBMCM-treated cells. Using a cutoff value of 2 fold, which is conventionally used by similar
studies, 3 genes were found to be up-regulated more than 2-fold. Only 1 gene appeared
to be down-regulated more than 2-fold during the differentiation process. A list of
identified genes is shown in Figure 23. Among the up-regulated genes during osteogenic
differentiation, biglycan coding for extracellular matrix protein is a prominent
osteoblastic marker which has previously been associated with the development and
function of osteoblasts and has been shown to play an important role in the bone
formation (Xu etal., 1998). Interestingly, TGF-pl involved in the enhancement of the
formation of extracellular matrix and inhibition of matrix degradation was also upregulated, including its receptor, TGF-PRl. In contrast, expression of the gene encoding
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67

68

69

70

71

72

MADH4

MADH5

MADH6

MADH7

MADH9

MMP10

MMP13

m /P 2

73

74

fvMPB

75

76

77

78

79

80

WSX1

MSX2

NFKB1

PDGFA

RUNX2

SERPINH1

81

82

83

84

85

86

87

88

SERPINH2

SOX9

SPARC

SPP1

TGFB1

TGFB2

TGFB3

TGFBR1

89

90

91

92

93

94

95

96

TGFBR2

TNF

TWIST

VCAM1

VDR

VEGF

VEGFB

VEBFC

97

98

99

100

101

102

103

104

PUC18

PUC18

PUC18

Blank

Blank

Blank

GAPD

GAPD

105

106

107

108

109

110

111

112

PPIA

PPIA

PPIA

PPIA

RPL13A

RPU13A

ACTB

ACTB

Figure 21. Grid located the spot corresponding to each gene in cDNA array.
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Table 9. List of names, accession numbers, and description of genes present in human
osteogenesis cDNA array

Position UniGene

Genebank Symbol Description

Gene name

1 Hs.250769

NM 000478

ALPL

ALP

2 Hs.79274

NM 001154

ANXA5

Annexin V

annexin v

3 Hs.74131

NM 000047

ARSE

Arylsulfatase E

ARSE

4 Hs.2558

X52698

BGLAP

Bone gamma-carboxyglutamate (gla) protein

Osteocalcin

5 Hs.821

J04599

BGN

Biglycan

Biglycan

6 Hs.1274

NM 006128

BMP1

Bone morphogenetic protein 1

BMP1

7 Hs.73853

NM 001200

BMP2

Bone morphogenetic protein 2

BMP2

8 Hs. 121507

NM 001201

BMP3

Bone morphogenetic protein 3

BMPS

g Hs.68879

NM 001202

BMP4

Bone morphogenetic protein 4

BMP4

10 Hs.1104

NM 021073

BMP5

Bone morphogenetic protein 5

BMP5

11 Hs.285671

NM 001718

BMP6

Bone morphogenetic protein 6

BMP6

12 Hs.170195

NM 001719

Bone morphogenetic protein 7

BMP7

13 Hs.99948

NM 001720

BMP7
BMP8

Bone morphogenetic protein 8

BMP8

14 Hs.2534

NM 004329

BMPR1A

Bone morphogenetic protein receptor, type IA

ALK-3

15 Hs.272429

U20760

CASR

Calcium-sensing receptor

CASR

16 Hs.75613

NM 000072

CD36

Homo sapiens CD36 antigen

CD36

17 Hs.180616

NM 005505

CD36L1

CD36 antigen-like 1

CD36L1

18 Hs.85963

AK025446

CD36L2

CD36 antigen-like 2

CD36L2

19 Hs.179729

NM 000493

COL10A1

Type X collagen a1

COL10A1

20 Hs.82772

NM 080629

COL11A1

Type XI collagen a1

COL11A1

21 Hs.101302

NM 004370

COL12A1

Type XII collagen a1

COL12A1

22 Hs.36131

BC014640

COL14A1

Type XIV collagen a1

COL14A1

23 Hs.83164

NM 001855

COL15A1

Type XV collagen a1

COL15A1

24 Hs.26208

NM 001856

COL16A1

Type XVI collagen a1

COL16A1

25 Hs.117938

NM 000494

COL17A1

Type XVII collagen a1

COL17A1

26 Hs.78409

AF18081

COL18A1

Collagen, type XVIII, alpha 1

Endostatin

27 Hs.89457

NM 001858

COL19A1

Type XIX collagen a1

COL19A1

Alkaline phosphatase, liver/bone/kidney

28 Hs.172928

NM 000088

COL1A1

Collagen type I (a)

COL1A1

29 Hs.81343

NM 001844

COL2A1

Type II collagen a1

COL2A1

30 Hs.119571

NM 000090

COL3A1

Collagen, type III, alpha 1

COL3A1

31 Hs.530
32 Hs.180828

NM 000091

COL4A3

Type IV collagen a3

COL4A3

NM 000092

COL4A4

Type IV collagen a4

COL4A4

33 Hs.169825

NM 033380

COL4A5

Type IV collagen a5

COL4A5

34 Hs.146428

NM 000093

COL5A1

Type V collagen a1

COL5A1

35 Hs.1640

NM 000094

COL7A1

Collagen, type VII, alphal

COL7A1

36 Hs.37165

NM 001852

COL9A2

Type IX collagen a2

COL9A2

37 Hs.1349

M11734

CSF2

Colony stimulating factor 2

GM-CSF
G-CSF

38 Hs.2233

X03438

CSF3

Colony stimulating factor 3

39 Hs.83942

NM 000396

CTSK

Cathepsin K

CTSK

40 Hs.76152

NM 001920

DCN

Decorin

Decorin
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Table 9. (continue)

Position UniGene

Genebank Symbol Description

Gene name

41 Hs.2230

X04571

EGF

Epidermal growth factor (beta-urogastrone)

EGF

42 Hs.77432

X00588

EGFR

Epidermal growth factor receptor

EGFR

43 Hs.75297

X51943

FGF1

Fibroblast growth factor 1 (acidic)

FGF1

44 Hs.284244

NM 002006

FGE2

Fibroblast growth factor 2 (basic)

FGE2
FGF3 (int-2)
FGFR1

45 Hs.37092

X14445

FGF3

Fibroblast growth factor 3

46 Hs.748

M34185

FGFR1

Fibroblast growth factor receptor 1

47 Hs.278581

M55614

FGFR1

Fibroblast growth factor receptor 2

FGFR2

48 Hs.1420

M64347

FGFR3

Fibroblast growth factor receptor 3

FGFR3

49 Hs.138671
50 Hs.287820

NM 002019

FLT1

Vascular endothelial growth factor receptor

FLT1

X02761

FN1

Fibronectin 1

Fibronectin-1

51 Hs.2171
52 Hs.168383

NM 004962

GDF10

Growth differentiation factor 10

BMP3B

NM 000201

ICAM1

Intercellular adhesion molecule 1 (CD54)

ICAM-1

53 Hs.85112

M27544

IGF1

Insulin-like growth factor 1

IGF-1

54 Hs.173231

X04434

IGF1R

insulin-like growth factor 1 receptor

IGF-1R

55 Hs.349109
56 Hs.116774

M29645

IGF2

Insulin-like growth factor 2

IGF-II

X68742

ITGA1

Integrin, alpha 1

Integrin a1

57 Hs.271986

X17033

ITGA2

Integrin, alpha 2

Integrin a2

58 Hs.265829
59 Hs.172631

M59911

ITGA3

Integrin, alpha 3

Integrin a3

J04145

ITGAM

Integrin, alpha M

Integrin aM

60 Hs.295726

NM 002210

ITGAV

Integrin, alpha V

Integrin aV

61 Hs.287797
62 Hs.79067

NM 002211

ITGB1

Integrin, beta 1

Integrin b1

U59912

MADH1

MAD homolog 1

SMAD1

63 Hs.82483

NM 005901

MADH2

MAD homolog 2

SMAD2

64 Hs.211578

NM 005902

MADH3

MAD homolog 3

SMAD3

65 Hs.75862
66 Hs.37501

U44378

MADH4

MAD homolog 4

DPC4/SMAD4

NM 005903

MADH5

MAD homolog 5

SMAD5

67 Hs,153863

NM 005585

MADH6

MAD homolog 6

SMAD6

68 Hs.100602

NM 005904

MADH7

MAD homolog 7

SMAD7

69 Hs.123119

NM 005905

MADH9

MAD homolog 9

SMAD9

70 Hs.2258

NM 002425

MMP10

Matrix metailoproteinase 10

MMP10

71 Hs.2936
72 Hs.111301

X75308

MMP13

Matrix metailoproteinase 13

Collagenase-3

J03210

MMP2

Matrix metailoproteinase 2

Gelatinase A

NM 002424

MMP8

Matrix metailoproteinase 8

MMP8

J05070

MMP9

Matrix metailoproteinase 9

Gelatinase B

73 Hs.73862
74 Hs.151738
75 Hs.1494

NM 002448

MSX1

Homeobox 7, MSH homeobox homolog 1

Hox7

76 Hs.89404

NM 002449

MSX2

MSH homeobox homolog 2

MSX2

77 Hs.83428

M58603

NFKB1

Nuclear factor of kappa enhancer in B cells 1

NFkB

78 Hs.37040
79 Hs.121895

X06374

PDGFA

Platelet-derived growth factor alpha

PDGFa

L40992

RUNX2

Runt-related transcription factor 2

CBFA1

80 Hs.241579

NM 004353

SERPINH1 Serine proteinase inhibitor, clade H, member 1

CBP1
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Table 9. (continue)

Position UniGene

Genebank Symbol Description

Gene name

81 Hs.9930

NM 001235

SERPINH2 Serine proteinase inhibitor, clade H, member 2

CBP2

82 Hs.2316

NM 000346

SOX9

SRY-box9

SOX9

83 Hs.111779

XM 003989

SPARC

Secreted protein, acidic, cysteine-rich

Osteonectin

84 Hs.313

M83248

SPP1

Secreted phosphoprotein 1

OPN

85 Hs.1103

X02812

TGFB1

Transform ng growth factor, beta 1

TGFbl

86 Hs.169300

M19154

TGFB2

Transform ng growth factor, beta 2

TGFb2

87 Hs.2025

NM 003239

TGFB3

Transform ng growth factor, beta 3

TGFb3

88 Hs.220

L11695

TGFBR1

Transform ng growth factor, beta receptor I

TGFBR1

89 Hs.82028

D50683

TGFBR2

Transform ng growth factor, beta receptor II

TGFBR2

90 Hs.241570

X01394

TNF

Tumor necrosis factor (TNF superfamily)

TNFa

91 Hs.66744

NM 000474

TWIST

Homolog of Drosophilia TWIST

TWIST

92 Hs.109225

M30257

VCAM1

Vascular cell adhesion molecule 1

VCAM-1

93 Hs.2062

NM 000376

VDR

Vitamin D hormone receptor

VDR

94 Hs.73793

NM 003376

VEGF

Vascular endothel al growth factor

VEGF

95 Hs.78781

U48801

VEGFB

Vascular endothel al growth factor B

VEGF-B

96 Hs.79141

X94216

VEGFC

Vascular endothel al growth factor C

VEGF-C

97 N/A

L08752

PUC18

PUC18 Plasmid DNA

pUC18

98 N/A

L08752

PUC18

PUC18 Plasmid DNA

pUC18

99 N/A

L08752

PUC18

PUC18 Plasmid DNA

pUC18

100 Blank

Blank

Blank

Blank

O

101 Blank

Blank

Blank

Blank

O

102 Blank

Blank

Blank

Blank

O

103 Hs.169476

M33197

GAPD

Glyceraldehyde-3-phosphate dehydrogenase

GAPDH

104 Hs.169476

M33197

GAPD

Glyceraldehyde-3-phosphate dehydrogenase

GAPDH

105 Hs.342389

NM 021130

PPIA

Peptidylprolyl isomerase A

cyclophilin A

106 Hs.342389

NM 021130

PPIA

Peptidylproiyl isomerase A

cyclophilin A

107 Hs.342389

NM 021130

PPIA

Peptidylprolyl isomerase A

cyclophilin A

108 Hs.342389

NM 021130

PPIA

Peptidylprolyl isomerase A

cyclophilin A
RPL13A

109 Hs.119122

NM 012423

RPL13A

Ribosomal protein L13a

110 Hs.119122

NM 012423

RPL13A

Ribosomal protein L13a

RPL13A

111 Hs.288061

X0Q351

ACTB

Beta Actin

b-actin

112 Hs.288061

XQ0351

ACTB

Beta Actin

b-actin
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Figure 22. Images of osteogenesis cDNA array used for gene expression analysis. HPO/LN-SHOl
cells were harvested for RNA isolation at day 7 and processes as described in “Materials and
Methods”. Total cell RNA (5ug) was used for analysis. C, control (cells without DBM-CM treatment);
T, treatment (cells with DBM-CM treatment).
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Figure 23. Comparison of gene expression of HPO/LN-SHOl cells without (control) and with
(treatment) DBM-CM addition using cDNA array analysis. The expression array signals for biglycans,
collagenl4Al, TGF-pl, and TGF-|3R1 are shown.
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for collagenl 4Al was down-regulated. This decrease might have implications during the
process o f bone development because collagenl 4Al occurs in virtually every collagen Icontaining tissue (periosteum, tendon, skeletal muscle, cardiac muscle, and nerve)
(Walchli etal., 1994).
2.5 Verification of expression of selected genes using RT-PCR analysis
To verify the cDNA array results, RT-PCR analysis was performed using Poly
(A)+RNA prepared from the same conditions as used in cDNA array studies. Among upregulated genes, biglycan found to be highly up-regulated gene was selected. Gene
encoding for collagenl4Al was chosen for down-regulated gene. A housekeeping
GAPDH gene, whose expression was unchanged during osteogenic differentiation, was
chosen to serve as an internal control. RT-PCR analysis of parallel samples was
consistent with the cDNA array data in that there was an increase in the level of biglycan
expression after day 7 of DBM-CM treatment (Figure 24). Also, in agreement with the
cDNA array analysis, expression of the gene encoding for collagenl4Al decreased after
day 7 of DBM-CM addition (Figure 26). Figure 25 and 27 shows the normalized gene
expression levels of RT-PCR bands for biglycan and collagenl 4 Al respectively. The
RT-PCR results demonstrated identical expression pattern for selected genes as revealed
by cDNA array analysis.
To examine the temporal expression of biglycan and collagenl 4Al in HPO cells
non-treated or treated with DBM-CM, poly (A)+ RNA was purified for RT-PCR analysis
at days 0, 4, 7, 10, and 14 in the absence or presence of DBM-CM. Figure 28 and 29
illustrate the time course of biglycan mRNA expression relative to that of GAPDH
mRNA in HPO cells without DBM-CM treatment. Figure 30 and 31 show time line of
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Figure 24. RT-PCR showing the up-regulation of biglycan in HPO/LN-SHOl cell line. GAPDH was
used as an internal control. C, control (cells without DBM-CM treatment); T, treatment (cells with
DBM-CM treatment); +, positive control in RT-PCR; -, negative control in RT-PCR; No RT, no
reverse transcriptase addition in RT-PCR.
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Figure 25. Densitography of the gel electrophoresis from Figure 24. Biglycan mRNA expression of
HPO/LN-SHOl cells in the absence (control) or presence of DBM-CM on day 7 was normalized with
that of the housekeeping gene GAPDH.
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Figure 26. RT-PCR showing the down-regulation of collagenl4Al in HPO/LN-SH01 cell line.
GAPDH was served as an internal control. C, control (cells without DBM-CM treatment); T, treatment
(cells with DBM-CM treatment); +, positive control in RT-PCR; -, negative control in RT-PCR;
No RT, no reverse transcriptase addition in RT-PCR.
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Figure 27. Densitography of the gel electrophoresis from Figure 26. Collagen 14A1 mRNA expression
of HPO/LN-SHOl cells in the absence (control) or presence of DBM-CM on day 7 was normalized
with that of the housekeeping gene GAPDH.
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Figure 28. Time course of biglycan expression in HPO/LN-SHOl
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Figure 29. Densitography of the gel electrophoresis from Figure 28. Expression profile of biglycan
from HPO/LN-SH01 cells without DBM-CM addition (control) was shown.
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biglycan mRNA expression relative to that of GAPDH mRNA in HPO cells after
addition of DBM-CM. On day 10 after DBM-CM treatment, biglycan mRNA expression
reached a peak and the level increased more than 3-fold compared with that of the culture
without treatment (Figure 32). It is intriguing to note that biglycan mRNA expression
level in the DBM-CM treated cells was approximately 2-fold higher than that of non
treated cells in every time point. In down-regulated gene, time course of collagenl4Al
expression relative to that of GAPDH mRNA was demonstrated in Figure 33 and 34 for
the non-treated HPO cells and in Figure 35 and 36 for the DBM-CM-treated HPO cells.
The results revealed that gene expression of collagenl4Al in the DBM-CM treated cells
decreased over time when compared with that in the untreated cells. The repression level
of collagen!4Al was greater than 2 fold on days 4, 7, and 14.
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Figure 31. Densitography of the gel electrophoresis from Figure 30. Expression profile of biglycan
from HPO/LN-SH01 cells with DBM-CM addition was shown.
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Figure 32, Comparison of biglycan mRNA expression by RT-PCR from time course study of
HPO/LN-SHOl cells.
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Figure 34, Densitography of the gel electrophoresis from Figure 33, Expression profile of
collagen!4Al from HPO/LN-SH01 cells without DBM-CM addition was shown.
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Figure 36. Densitography of the gel electrophoresis from Figure 35. Expression profile of
collagen 14A1 from HPO/LN-SH01 cells with DBM-CM addition was shown.
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Figure 37. Comparison of collagen 14A1 mRNA expression by RT-PCR from time course study of
HPO/LN-SHOl cells.
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DISCUSSION

Bone morphogenetic proteins are originally identified as protein regulators of
cartilage and bone formation. BMPs have been implicated in embryogenesis and
morphogenesis of various tissues and organs. BMPs can regulate growth, differentiation,
chemotaxis and apoptosis in a variety of cell types, including mesenchymal, epithelial,
hematopoietic and neuronal cells. BMP-4 plays an essential role in the onset of bone
formation, dorsal/ventral patterning (Graff, 1997) and has also been implicated in the
commitment of embryonic mesodermal cells to a hematopoietic fate in a number of
system (Leong et al., 1996; Reddi, 1998; Wozney, 1992). BMP-4 is also involved in
prenatal and postnatal endochondral ossification. Deregulation of BMP-4 expression is
associated with fibrodysplasia ossificans progressiva (Xu et al., 1998; Shore et al., 1998).
In addition to this heterotopic bone formation, it also is suggested that BMP-4 plays a
role in bone fracture repair. It has become evident that early in the process of fracture
healing, the concentration of BMP-4 increases (Bostrom et al., 1995). Recombinant
human BMP-4 (rhBMP-4) effectively enhances new bone formation and accelerates
fusion of the rabbit posterolateral posterior spinal fusion model in a dose-dependent
fusion (Cheng et al., 2002; Guo et al., 2002). Additionally, the recent studies showed
that rhBMP-2-containing demineralized bone allograft resulted in a dose-dependent
increase in new bone formation (Schwartx et al., 1998; Niederwanger et al., 1996). It is
generally accepted that the BMPs present in demineralized bone materials reflect to their
ability to induce new bone formation.
The current study investigated whether BMP-4 could be identified and quantitated
in the protein extracts of DBM. The data demonstrated that BMP-4 was present and
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could be detected in the protein extracts of DBM by using Western blotting and ELISA.
A recent study has shown that BMP-4 was observed in the extracts of demineralized
freez-dried bone allograft (DFDBA) by slot blot analysis (Shigeyama et a l, 1995). It is
plausible that BMPs other than BMP-4 are also present in the extracts of DFDBA since
BMP-2 and BMP-7 have also been demonstrated to be present in the extracts of DFDBA,
but we did not specifically investigate for these. Both BMP-2 and BMP-7 are also the
most osteoinductive proteins that are able to induce heterotopic bone formation (Wozney
et a l, 1998). Future investigations with BMP-2 and BMP-7 will need to determine the
presence and quantities of BMP-2 and BMP-7 in the protein extracts of DBM as they are
relevant to the potential for induction of new bone formation.
In apparent contrast to the results of this study, BMP-2 and BMP-4 were reported
to be undetectable in the extracts of DFDBA by immunoprecipitation coupled with
Western blot analysis (Li et a l, 2000). This discrepancy could be attributable to different
extraction methods, inability of the antibody used in that study to recognize its target
epitope, and/or sensitiviy of assays utilized. The results of the present study suggest that
BMPs are covered by the minerals and tightly associated with collagen fibers.
Furthermore, the amount of BMPs is small. Therefore, BMPs would not be detectable
without extensive demineralization and appropriate extraction. This may explain the
failure of others to detect BMP-4. However, this finding in the present study is in
accordance with that of Wozney (Wozney, 1992), who reported that BMPs are found in
microgram quantities per kilogram of cortical bone. We demonstrated that the level of
extractable BMP-4 in DBM was in the range of nanogram per gram of DBM.
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The data of this study revealed that non-demineralized bone matrix did not yield
extractable BMP-4 whereas slightly demineralized bone matrix provided a degree of
extractability of BMP-4, as the mineral content decreased the extractability of BMP-4
increased. Expectedly, the observation that the non-demineralized bone matrix showed
no detectable BMP-4 level supports the widely known concept that BMPs are trapped by
the minerals, and demineralization will expose BMPs relatively proportional to the
degree of demineralization. Obviously, the more bone matrix is demineralized, the more
minerals are removed, and the more BMPs become liberated and extractable from the
DBM. Additionally, in the particle size study, we also illustrated that bone particle size
had a striking effect on the extractability ofBMP-4 from DBM. Bone particles between
550 micron and 710 micron provided for the highest levels of extractable BMP-4 and
appear to represent the optimal size range in that bone particles of larger or smaller sizes
provided lower extractable BMP-4 levels. Interestingly, this finding is in agreement with
the previous observation in our laboratory in that DBM in the 550 to 710 micron bone
particle size range provided for maximum osteoinductive potential in in vitro and in vivo
bioassays (Zhang et al., 1997).
For the present size study, different particle sizes of DBM were demineralized for
equivalent periods of time to mimic the actual process of demineralizing bone in the 250
micron to 850 micron particle size range. The previous study reported that different
particle-sized DBM contained different levels of residual calcium where smaller particle
sized DBM was more readily demineralized than larger particle-sized DBM (Zhang et al.,
1997). The current study demonstrated that bone particle size had a dramatic effect on
the extractability ofBMP-4 in DBM. From the 550 to 710 micron particle size range of
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DBM to the <250 micron particle size range of DBM, as the particle size decreased the
extractability ofBMP-4 from DBM declined. DBM particles less than 250 micron
provided for minimum level of extractable BMP-4 among all size groups tested. This
reduction may be attributable to degradation ofBMP-4 during the process of
demineralization.
Additional data presented in this study revealed that there were donor age and
gender-related effects on the extractability ofBMP-4 from DBM. DBM derived from
female donors appears to contain maximally and significantly more extractable BMP-4
when derived from donors in the age group 0 to 25 years of age than from donors in all
other age groups tested, whereas there was no statistically significant difference in the
extractable BMP-4 among DBM samples derived from male donors. When compared
within each of age group, DBM from male donors in the age group 26 to 44 years of age
and 45 years of age and older possessed more extractable BMP-4 than those from female
donors in the same age group. However, in general, there was no statistically significant
different in the extractable BMP-4 levels of DBM between male and female donors.
Collectively, the levels of extractable BMP-4 and the osteoinductive potential of
DBM derived from 40 donors were investigated. The data designated a direct correlation
between the extractable BMP-4 levels in DBM using the quantitative in vitro assay and
the osteoinductivity of DBM from the in vivo bioassay. A linear regressional analysis
between these 2 assessment methods exhibited a correlation coefficient (R) of 0.74
(P < 0.001). Therefore, the quantitative BMP-4 in vitro assay could be an alternative
means of assessing the capability of DBM to induce new bone formation. Additional
data suggest that availability (i.e., extractability) ofBMP-4 depends upon the
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demineralization process. Hence, it is essential to the production of a reproducibly
osteoinductive DBM product that the demineralization process be controlled and
reproducible irrespective of the nature of the bone materials being demineralized.
The principal benefit of the quantitative BMP-4 in vitro assay for quantitating the
osteoinductivity of demineralized bone products is time saving; results are available
within 2 days. In contrast, the in vitro cell culture based and in vivo animal based
bioassays required a minimum of 1 week and 4 weeks respectively to obtain information
which may be used as a quality assessment criteria for release of produced DBM.
Moreover, these 2 bioassays are labor consuming and involve a considerable amount of
work, including complicated biological systems. In addition, surgical problems with
implanted animals can be eliminated. There is no need to concern about immunological
and inflammatory responses of tested animals to demineralized bone products. The
quantitative BMP-4 in vitro assay described in the current study is sensitive,
reproducible, inexpensive, and requires less than 2 days to perform.
In this study, gene expression profiling of osteogenic differentiation in human
periosteal (HPO/LN-SHOl) cells was also examined. Osteogenic differentiation is a
complex process and involves distinct genotypic changes that are accompanied by
specific phenotypic alterations. Recent advances in cDNA gene expression array
technology allow for simultaneous monitoring of a number of known and unknown genes
in parallel. cDNA expression arrays are rapidly becoming the method of choice to
investigate gene expression profiles in various specialized system. In the current study
human osteogenesis gene arrays were utilized to differentially display bone-related genes
that may play crucial roles in osteoblast development. This study investigated the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

106
expression of over 96 genes involved in the regulation of osteogenic differentiation. The
observation from this study revealed that expression of biglycan was up-regulated
whereas the expression of collagenl4Al was down-regulated in the DBM-CM treated
cultures compare with the non-treated cultures.
Although bone is a highly specialized tissue, osteoblasts are very similar to
fibroblasts in terms of gene expression (Ducy et al., 2000). A characteristic feature of
osteoblasts is the secretion and processing of extracellular matrix. The strongest
modulations were observed in the cDNA array experiments for extracellular matrix
genes, with particularly striking up-regulation of small leucine-rich proteoglycan,
biglycan. Proteoglycans play a role in matrix assembly and can promote in vitro matrix
mineralization (Boskey et al., 1997). The result from the time course study of biglycan is
in agreement with the model of osteoblast differentiation in which osteoblast
differentiation is followed by matrix deposition and matrix maturation. This cDNA array
study thus may extend current knowledge about the mechanism whereby osteoblasts
deposit bone matrix.
In addition, other genes, such as alkaline phosphatase (ALP), Runx2, insulin-like
growth factor-1 (IGF-1), and vascular endothelial growth factor (VEGF) were slightly
up-regulated. Their induction level on cDNA array was less than 2-fold and therefore not
included in RT-PCR analysis. Furthermore, it is essential to realize that unknown
relevant osteoblast-specific genes might not be present on the cDNA arrays used in this
study.
The data derived from this type of approach are broadly descriptive. However,
the analysis presented in this study offers a screening method and a dynamic picture of
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gene expression during osteogenic differentiation. Other reports have shown in which
gene expression during osteoblast differentiation has been investigated on a large scale by
using gene expression array technology (Beck et al., 2001; Locklin et al., 2001). It is
important to note that accurate comparison of these studies is difficult for several reasons:
(1) the cDNA used in this study differs from the arrays used in other studies, therefore
different genes are screened; (2) studies are performed in different cell lines; (3) different
agents or inducers of osteoblast differentiation such as P-glycerophosphate, ascorbic acid,
BMP, and conditioned media are used; and (4) expression analysis is performed at
different time points. The ability to compare data collected on hundreds of genes under
one set of conditions with data from other system results in overall understanding of the
molecular basis of osteogenesis. These data are valuable not just for a better
understanding of osteogenesis but also for the comparison with other tissue types.
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SUMMARY

In summary, the present study established and validated the quantitative in vitro
assay for the assessment of osteoinductive potential of human demineralized bone matrix
In addition, this study investigated the relationships between extractability ofBMP-4 and
the residual calcium content in the DBM, the relationship between the extractability of
BMP-4 and bone particle size, and the relationship between the extractability ofBMP-4
and donor age and gender. The study validated the quantitative in vitro method used for
the assessment of the osteoinductivity of DBM. Furthermore, gene expression profiling
of osteogenic differentiation in human periosteal cells was investigated. The results
provided insight to the biological process of osteogenic differentiation in human
periosteal cells.
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